Top

Sanam Loghavi, M.D.

Department of Hematopathology, Division of Pathology-Lab Medicine Div

Meet Sanam Loghavi, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Hematopathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX

Medical Director, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004	Islamic Azad University, Tehran, IR, MD

Postgraduate Training

2014-2015	Clinical Fellowship, Molecular Pathology, UT MD Anderson Cancer Center, Houston, Texas
2013-2014	Clinical Fellowship, Hematopathology, UT MD Anderson Cancer Center, Houston, Texas
2012-2013	Clinical Fellowship, Surgical Pathology, UT MD Anderson Cancer Center, Houston, Texas
2008-2012	Clinical Residency, Anatomic and Clinical Pathology, Cedars-Sanai Medical Center, Los Angeles, California

Licenses & Certifications

2016	American Board of Pathology-Molecular Genetic Pathology
2014	Texas Medical Board
2014	American Board of Pathology-Hematopathology
2012	American Board of Pathology-Anatomic and Clinical Pathology
2010	Medical Board of California

Experience & Service

Faculty Academic Appointments

Assistant Professor, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021

Chief Fellow, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015

Chief Fellow, Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2013

Chief Resident, Department of Pathology/Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 2011 - 2012

Administrative Appointments/Responsibilities

Medical Director -ECOG ACRIN Leukemia Bank, Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, Texas, 2017 - Present

Other Professional Positions

Member, Cedars-Sinai Medical Center Housestaff Executive Committee, Los Angeles, CA, 2011 - 2012

Member, College of American Pathologist-Residents' Forum, Los Angeles, CA, 2009 - 2011

Research Assistant, Stanford School of Medicine, Palo Alto, CA, 2007 - 2008

Extramural Institutional Committee Activities

Member, SOHO Scientific Committee, Society of Hematology and Oncology, 2024 - Present

Ambassador, SOHO Ambassador Program, Society of Hematology and Oncology, 2024 - Present

Member, PRS Executive Council, The University of Texas MD Anderson Cancer Center, 2016 - 2019

Editorial Activities

Editor In Chief, ASH Image Bank, 2023 - Present

Assistant Editor of Hematology, Lab Medicine, 2020 - Present

Editorial Board Member, Journal of Immunotherapy and Precision Oncology, 2020 - Present

Editorial Intern, Lab Medicine, 2019 - 2020

Honors & Awards

2023	Faculty Educator of the Year, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center
2023	Berard-Dorfman Founders Award for Young Investigators, Society for Hematopathology
2021	Pathology Advancement Award, College of American Pathologists
2019 - 2020	Faculty Teaching Award 2019-2020, Department of Hematopathology-MDACC
2019	40 Under Forty, American Society of Clinical Pathology
2015	Shannon Timmins Fellowship Award in Leukemia Research, MD Anderson Cancer Center
2014	Fellow's Research Funding Grant, The University of Texas MD Anderson Cancer Center, Division of Pathology
2014	IPANA Annual Trainee Award, Iranian Pathologist Association of North America
2011 - 2012	Leo G. Rigler, M.D. Award Outstanding houseofficer, Cedars-Sinai Medical Center

Professional Memberships

American Society of Hematology

2017 - Present

Harris County Medical Society

2017 - Present

American Association for Molecular Pathology

2014 - Present

Society of Hematologic Oncology

2014 - Present

European Association for Hematopathology

2014 - Present

American Society of Hematopathology

2013 - Present

Society of Hematopathology

2013 - Present

U.S. and Canadian Academy of Pathologist

2008 - Present

College of American Pathologists

2008 - Present

American Society of Clinical Pathology

2008 - Present

Selected Presentations & Talks

Local Presentations

2025. Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States. Invited. Emil J Freireich Leukemia Hematology Grand Rounds. Houston, Texas, US.
2024. The Current State of Measurable Residual Disease Assessment in Acute Myeloid Leukemia. Invited. Division of Pathology and Laboratory Medicines Joanne Vandenberg Hill Lecture. Houston, Texas, US.
2022. Updated Classification of Myeloid Neoplasms. Conference. Updated Classification of Myeloid Neoplasms. Houston, TX, US.
2019. Clonal hematopoiesis and its implications for disease monitoring in acute myeloid leukemia. Conference. Clonal hematopoiesis and its implications for disease monitoring in acute myeloid leukemia. Houston, TX, US.
2016. EBV + T-Cell lymphoma. Conference. EBV + T-Cell lymphoma. Houston, TX, US.

National Presentations

2025. Optimal use of Optical Genome Mapping and RNA-translocation panel in frontline AML. Invited. iWAL 2025. Washington, DC, US.
2025. MRD is Universally Accepted Assay/Standard of Care for Management of Fit Adults with Newly Diagnosed AML. Invited. iWAL 2025. Washington, DC, US.
2025. Prognostic Implications of Measurable Residual Disease in Acute Myeloid Leukemia (Flow Cytometry). Invited. iWAL 2025. Washington, DC, US.
2025. Harmonizing WHO and International Consensus Classification (ICC) Classification in AML and MDS. Invited. Pan Pacific Leukemia Conference. Maui, HI, US.
2025. Diagnostic and Molecular Work-up of Newly Diagnosed AML – The Pathologist’s Perspective. Invited. AML ALL US Focus 2025. Los Angeles, CA, US.
2025. Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States. Invited. Oregon Health- Pathology Grand Rounds. Oregon, Colorado, US.
2024. Navigating the WHO and ICC Classification for Myeloid Malignancies: A Primer for Everyday Practice. Conference. CAP Annual Meeting. Las Vegas, NV, US.
2024. Classification of Myelodysplastic Neoplasms. Invited. MPN/MDS US Focus Meeting. La Jolla, CA, US.
2024. Beyond the Ring: The Genetically Diverse Landscape of SF3B1 mutated Myelodysplastic Neoplasms. Invited. 2024 Hematopoietic Stem Cell and Myelodysplastic Symposium. Houston, TX, US.
2023. Help! Making Sense of the ICC/ELN Classifications and Where Do They Fit with the WHO 5th ed? What Should the Practicing Hematologist/Oncologist Be Aware of?. Conference. Help! Making Sense of the ICC/ELN Classifications and Where Do They Fit with the WHO 5th ed? What Should the Practicing Hematologist/Oncologist Be Aware of?. Virtual, US.
2023. MDS classification: ICC 2022. Conference. MDS classification: ICC 2022. Phoenix, AZ, US.
2022. Updates on Myeloproliferative Neoplasms. Conference. Updates on Myeloproliferative Neoplasms. Virtual, US.
2022. The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist. Conference. The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist. New Orleans, LA, US.
2022. Molecular Analysis of Acute Myeloid Leukemia in Remission. Conference. Molecular Analysis of Acute Myeloid Leukemia in Remission. Los Angeles, CA, US.
2021. Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. Conference. Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. Atlanta, GA, US.
2021. Myeloid Neoplasms-Hematopathology. Conference. Myeloid Neoplasms-Hematopathology. Mauii, HI, US.
2021. Clonal hematopoiesisand its implications for measurable residual disease (MRD) monitoring in acute myeloid leukemia. Conference. Clonal hematopoiesisand its implications for measurable residual disease (MRD) monitoring in acute myeloid leukemia. Virtual, US.
2021. Secondary AML Through the Microscope: A Pathology-informed Guide to Modern Diagnostic and Treatment Principles. Conference. PeerView. Virtual, US.
2021. The evolving role of flow cytometry immunophenotypingin the diagnosis and surveillance of myeloid neoplasms. Conference. The evolving role of flow cytometry immunophenotypingin the diagnosis and surveillance of myeloid neoplasms. Virtual, US.
2021. Optimizing Care for High-Risk Myeloid Cancers. Conference. PeerView. Virtual, US.
2020. Patient-Centered Pathology Education: A Timely and Unique Window of Opportunity. Conference. Patient-Centered Pathology Education: A Timely and Unique Window of Opportunity. San Diego, CA, US.
2020. Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations. Conference. Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations. Los Angeles, US.
2020. Characterization of Bone Marrow Morphologic and Genetic Features of Myeloid Neoplasms with Germline DDX41 Mutation in 10 Distinct Pedigrees. Conference. Characterization of Bone Marrow Morphologic and Genetic Features of Myeloid Neoplasms with Germline DDX41 Mutation in 10 Distinct Pedigrees. Los Angeles, CA, US.
2020. Importance of Bone Marrow Morphologic Features for Surveillance of Patients with Myelofibrosis Following Molecular Clearance after Stem Cell Transplant. Conference. Importance of Bone Marrow Morphologic Features for Surveillance of Patients with Myelofibrosis Following Molecular Clearance after Stem Cell Transplant. Los Angeles, CA, US.
2020. Plasmablastic Lymphoma Mutational Profile is Characterized by MYC, STAT3 and PRDM1/Blimp1 Mutations. Conference. Plasmablastic Lymphoma Mutational Profile is Characterized by MYC, STAT3 and PRDM1/Blimp1 Mutations. Los Angeles, CA, US.
2020. A Large Multicenter Series of Post-Transplant Lymphoproliferative Disorders Involving the Gastrointestinal Tract and Liver. Conference. A Large Multicenter Series of Post-Transplant Lymphoproliferative Disorders Involving the Gastrointestinal Tract and Liver. Los Angeles, CA, US.
2020. t(11;16)(q23;p13) and t(2;11)(p21;q23) in Hematologic Neoplasms: Presumptive Evidence of Myelodysplasia Revisited. Conference. t(11;16)(q23;p13) and t(2;11)(p21;q23) in Hematologic Neoplasms: Presumptive Evidence of Myelodysplasia Revisited. Los Angeles, CA, US.
2020. CD123 Overexpression Significantly Varies in Different Subtypes of Adult Acute Myeloid Leukemia. Conference. CD123 Overexpression Significantly Varies in Different Subtypes of Adult Acute Myeloid Leukemia. Los Angeles, CA, US.
2019. Myeloid neoplasm with cryptic PDGRB rearrangement. Conference. Myeloid neoplasm with cryptic PDGRB rearrangement. Phoenix, AZ, US.
2019. Myeloid Neoplasm with Cryptic PDGFRB Rearrangement. Conference. Myeloid Neoplasm with Cryptic PDGFRB Rearrangement. Phoenix, AZ, US.
2018. B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow. Conference. B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow. Huntington Beach, CA, US.
2018. Distinct Genetic Features of Myelodysplastic Syndromes as Defined in the Revised 2016 World Health Organization Classification. Conference. Distinct Genetic Features of Myelodysplastic Syndromes as Defined in the Revised 2016 World Health Organization Classification. Vancouver, US.
2017. Chronic myelomonocytic leukemia & Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia. Conference. Chronic myelomonocytic leukemia & Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia. Chicoago, IL, US.
2016. Ultradeep Sequencing Using Semiconductor-Based High-Throughput Next- Generation Sequencing Platforms for Cell-Free DNA Genotyping in Patients with Solid Tumors. Conference. Ultradeep Sequencing Using Semiconductor-Based High-Throughput Next- Generation Sequencing Platforms for Cell-Free DNA Genotyping in Patients with Solid Tumors. Charlotte, NC, US.
2016. Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. Conference. Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. Charlotte, NC, US.
2016. Myeloid Neoplasms with Recurrent GNAS Mutations. Conference. Myeloid Neoplasms with Recurrent GNAS Mutations. Charlotte, NC, US.
2016. MYC protein expression as prognostic in acute myeloid leukemia. Conference. MYC protein expression as prognostic in acute myeloid leukemia. Chicago, IL, US.
2016. Bone Marrow and Extramedullary Lesions in Patients with Myeloproliferative Neoplasms Exhibit Similar miRNA Profiles. Conference. Bone Marrow and Extramedullary Lesions in Patients with Myeloproliferative Neoplasms Exhibit Similar miRNA Profiles. Seattle, WA, US.
2016. De Novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. Conference. De Novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. Seattle, WA, US.
2015. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. Conference. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. Austin, TX, US.
2015. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. Conference. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. Austin, TX, US.
2015. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia The Journal of Molecular Diagnostics. Conference. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia The Journal of Molecular Diagnostics. Austin, TX, US.
2015. Improving Molecular Testing in Patients with Unexpected Acute Myeloid Leukemia Using Interlaboratory and Interdisciplinary Communication. Conference. Improving Molecular Testing in Patients with Unexpected Acute Myeloid Leukemia Using Interlaboratory and Interdisciplinary Communication. Austin, TX, US.
2015. Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. Conference. Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. Houston, TX, US.
2015. Flow Cytometric Immunophenotypic Characterization of Angioimmunoblastic T-cell Lymphoma. Conference. Flow Cytometric Immunophenotypic Characterization of Angioimmunoblastic T-cell Lymphoma. Boston, MA, US.
2015. Dealing with the Incidental: Experiences Implementing the ACMG Guidelines for Reporting Germline Findings in a Comprehensive Somatic Mutation Assay. Conference. Dealing with the Incidental: Experiences Implementing the ACMG Guidelines for Reporting Germline Findings in a Comprehensive Somatic Mutation Assay. Boston, MA, US.
2015. Evaluation of Myelodysplastic Features and Correlation With Cytogenetic Findings in Hepatosplenic T-Cell Lymphoma: Analysis of 28 Patients. Conference. Evaluation of Myelodysplastic Features and Correlation With Cytogenetic Findings in Hepatosplenic T-Cell Lymphoma: Analysis of 28 Patients. Boston, MA, US.
2015. DNMT3A Mutation as a Molecular Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. Conference. DNMT3A Mutation as a Molecular Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. Boston, MA, US.
2015. Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Megakaryocytic Features. Conference. Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Megakaryocytic Features. Boston, MA, US.
2015. De Novo Myelodysplastic Syndromes With Fibrosis Exhibit an Increased Frequency of TP53 Mutations and p53 Overexpression. Conference. De Novo Myelodysplastic Syndromes With Fibrosis Exhibit an Increased Frequency of TP53 Mutations and p53 Overexpression. Boston, MA, US.
2015. CD5 Positive De Novo Diffuse Large B Cell Lymphoma: Clinicopathologic Findings and Correlation With Outcome. Conference. CD5 Positive De Novo Diffuse Large B Cell Lymphoma: Clinicopathologic Findings and Correlation With Outcome. Boston, MA, US.
2015. B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma – A Series of 24 Patients. Conference. B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma – A Series of 24 Patients. Boston, MA, US.
2015. Flow Cytometric Immunophenotypic Characterization of Angioimmunoblastic T-cell Lymphoma. Conference. Flow Cytometric Immunophenotypic Characterization of Angioimmunoblastic T-cell Lymphoma. Houston, TX, US.
2014. Clinical and Biological Features of Primary Testicular B-Cell Lymphoma -a Single-Institution Study of 89 Cases. Conference. Clinical and Biological Features of Primary Testicular B-Cell Lymphoma -a Single-Institution Study of 89 Cases. San Francisco, CA, US.
2014. Endoscopic Mucosal Resection (EMR) for the Management of Solitary Extramedullary Plasmacytoma of the Esophagus. Conference. Endoscopic Mucosal Resection (EMR) for the Management of Solitary Extramedullary Plasmacytoma of the Esophagus. Philadelphia, PA, US.
2014. DNMT3A Mutations Exert a Dominant Adverse Effect in De Novo Acute Myeloid Leukemia with Concurrent FLT3 And NPM1 Mutations. Conference. DNMT3A Mutations Exert a Dominant Adverse Effect in De Novo Acute Myeloid Leukemia with Concurrent FLT3 And NPM1 Mutations. Houston, TX, US.
2014. Extramedullary Epstein-Barr Positive Plasmacytoma in Immunocompetent patients. Conference. Extramedullary Epstein-Barr Positive Plasmacytoma in Immunocompetent patients. Houston, TX, US.
2014. Acute Myeloid Leukemia Cases with t(v;5q33-34) Do Not Always Have Myelodysplastic Features But are Associated with Poor Outcome. Conference. Acute Myeloid Leukemia Cases with t(v;5q33-34) Do Not Always Have Myelodysplastic Features But are Associated with Poor Outcome. Houston, TX, US.
2014. Clinical significance of MYC expression in acute myeloid leukemia. Conference. Clinical significance of MYC expression in acute myeloid leukemia. Chicago, IL, US.
2014. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. Conference. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. Baltimore, MD, US.
2014. FOXP3+Tumor Infiltrating Lymphocytes in EBV-Positive Lymphoepithelioma-Like Gastric Carcinoma: Clinicopathologic Features and Survival. Conference. FOXP3+Tumor Infiltrating Lymphocytes in EBV-Positive Lymphoepithelioma-Like Gastric Carcinoma: Clinicopathologic Features and Survival. San Diego, CA, US.
2014. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. Conference. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. San Diego, CA, US.
2014. Tumor Size Correlates with Survival in Melanomas Associated with Conventional or Cellular Blue Nevi or Displaying Blue Nevus-Like Features (So Called Malignant Blue Nevus ). Conference. Tumor Size Correlates with Survival in Melanomas Associated with Conventional or Cellular Blue Nevi or Displaying Blue Nevus-Like Features (So Called Malignant Blue Nevus ). San Diego, CA, US.
2014. Diagnostic and Prognostic Utility of Plasma microRNA Signatures in Patients with Myelodysplastic Syndromes. Conference. Diagnostic and Prognostic Utility of Plasma microRNA Signatures in Patients with Myelodysplastic Syndromes. San Diego, CA, US.
2013. BCR-ABL1+myeloproliferative neoplasm with myelomastocytic differentiation and increased blasts. Conference. BCR-ABL1+myeloproliferative neoplasm with myelomastocytic differentiation and increased blasts. Houston, TX, US.
2012. Cutaneous IgG4 Lesions. Conference. Cutaneous IgG4 Lesions. San Diego, CA, US.
2011. CINtec® PLUS for triage of women with low grade squamous intraepithelial lesions on Pap smear. Conference. CINtec® PLUS for triage of women with low grade squamous intraepithelial lesions on Pap smear. Baltimore,, MD, US.
2011. CINtec® PLUS immunostain is better than p16 or ki67 for triage of women with abnormal Pap smears. Conference. CINtec® PLUS immunostain is better than p16 or ki67 for triage of women with abnormal Pap smears. Baltimore, MD, US.
2011. Cranial-extracranial fasciitis: a clinical, radiological and pathological analysis. Conference. Cranial-extracranial fasciitis: a clinical, radiological and pathological analysis. Seattle, WA, US.
2011. Human Sparganosis: Dermatopathology Update with Mini symposiums on Inflammatory Dermatoses, Melanocytic Lesions and Soft Tissue, Cutaneous Infections and Infestations. Conference. Human Sparganosis: Dermatopathology Update with Mini symposiums on Inflammatory Dermatoses, Melanocytic Lesions and Soft Tissue, Cutaneous Infections and Infestations. Boston, MA, US.
2011. What is the Optimal Number of CINtec (R) PLUS Positive Cells for Detection of High Grade Cervical Intraepithelial Neoplasia?. Conference. What is the Optimal Number of CINtec (R) PLUS Positive Cells for Detection of High Grade Cervical Intraepithelial Neoplasia?. San Antonio, TX, US.
2010. The Prevalence of Merkel Cell Carcinoma Polyomavirus in Squamous Cell Carcinoma and Sun Damaged skin: A Immunohistochemical Study. Conference. The Prevalence of Merkel Cell Carcinoma Polyomavirus in Squamous Cell Carcinoma and Sun Damaged skin: A Immunohistochemical Study. Atlanta, GA, US.
2010. Malignant Myopericytoma. Conference. Malignant Myopericytoma. Los Angeles, CA, US.
2010. Low Grade Vulvar Intraepithelial Lesions: A Correlation Study among Koilocytosis, Viral Load, Ki-67, and P16. Conference. Low Grade Vulvar Intraepithelial Lesions: A Correlation Study among Koilocytosis, Viral Load, Ki-67, and P16. Washington, DC, US.
2010. Immunoreactivity of Smoothelin in Skin and Superficial Soft Tissue Tumors and Reactive Proliferations. Conference. Immunoreactivity of Smoothelin in Skin and Superficial Soft Tissue Tumors and Reactive Proliferations. Washington, DC, US.
2010. The Usefulness of Fluorescence In Situ Hybridization in Diagnosis of Myelodysplastic Syndromes. Conference. The Usefulness of Fluorescence In Situ Hybridization in Diagnosis of Myelodysplastic Syndromes. Washington, DC, US.
2009. Acquired perforating dermatosis in a renal transplant recipient with Hepatitis C. Conference. Acquired perforating dermatosis in a renal transplant recipient with Hepatitis C. Chicago, IL, US.
2007. Abnormal Myometrial Vasculature Explains Some Cases of Menorrhagia. Conference. Abnormal Myometrial Vasculature Explains Some Cases of Menorrhagia. Boston, MA, US.

International Presentations

2025. Role of flow cytometry in the multi-disciplinary diagnostic approach of MDS according to WHO classification 2022. Invited. European Society for Clinical Cell Analysis (ESCCA) Annual Meeting. Montpellier, FR.
2025. Clinical Case Session- Expert Hematopathology Review. Invited. European Hematology Association Annual Meeting. Milan, IT.
2025. Data Driven CLassificaiton of Myeloid Neoplasms. Invited. Therapy and Biology of Myeloid Neoplasms. Crete, GR.
2025. Distinguishing CCUS & MDS – morphology or genes?: Sanam Loghavi. Invited. Intercepting Blood Cancers. Nice, FR.
2025. Update on MDS Classification Harmonization: Is an 'Immune Score' Next?. Invited. i4MDS. Hauge, NL.
2024. Updates in AML Classification Systems and Incorporating Molecular Information into Optimizing Future Classification Systems to Help Optimally Guide Treatment Decision Making. Invited. AML-ALL EU Focus Meeting Updating Knowledge & Clinical Practice in 2024. London, GB.
2024. Updated Classification of Myeloid Neoplasms: AML and MDS. Invited. McMaster Hematology Grand Rounds. Hamilton, CA.
2024. BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML. Poster. 2nd Probing Human Disease using Single-Cell Technologies Conference. Cancun, MX.
2024. Hypoplastic MDS/ Aplastic anemia-diagnostic challenges. Invited. i4MDS. Hague, NL.
2023. Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia. Conference. American Society of Hematology Annual Meeting. San Diego, US.
2023. Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1-Mutated Myeloid Malignancies. Conference. American Society of Hematology. San Diego, US.
2023. The significance of variant allele frequency in SF3B1 mutated myelodysplastic neoplasms/syndromes. Poster. American Society of Hematology Annual Meeting. San Diego, US.
2023. Low grade B-cell Lymphoproliferative Disorders of Bone Marrow and Blood. 34th Annual Congress of the Arab Division of the International Academy of Pathology. Doha, QA.
2022. Lymphoproliferative disorders of the GI tract. Conference. Lymphoproliferative disorders of the GI tract. Tehran, IR.
2022. Technical and Diagnostic Considerations in Eosinophil, Mast Cell, Basophil, and Plasmacytoid Dendritic Cell Disorders. Conference. Technical and Diagnostic Considerations in Eosinophil, Mast Cell, Basophil, and Plasmacytoid Dendritic Cell Disorders. Montreal, CA.
2022. Chronic Myeloid Stem Cell Neoplasms. Conference. Chronic Myeloid Stem Cell Neoplasms. Montreal, CA.
2022. Oligoblastic Acute Myeloid Leukemia With NPM1 Mutation Associated with Leukemic Pleural Effusion in A Patient With Down Syndrome. Conference. Oligoblastic Acute Myeloid Leukemia With NPM1 Mutation Associated with Leukemic Pleural Effusion in A Patient With Down Syndrome. Florence, IT.
2021. Clonal Hematopoiesis of Emerging Significance. Conference. Clonal Hematopoiesis of Emerging Significance. Virtual, AU.
2020. Molecular updates in Hematopoietic Neoplasms. Conference. Molecular updates in Hematopoietic Neoplasms. Bangkok, TH.
2020. Lymph Node Pathology. Conference. Lymph Node Pathology. Chennai, IN.
2019. Myeloid Neoplasms with t(11;16)(q23;p13): A Study of 11 Cases. Conference. Myeloid Neoplasms with t(11;16)(q23;p13): A Study of 11 Cases. Vancouver, CA.
2018. Update on T cell lymphomas. Conference. Update on T cell lymphomas. Dead Sea, JO.
2018. Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. Conference. Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. Vancouver, CA.
2018. The Work-up of Patients with Hypereosinophilia at a Tertiary Referral Center. Conference. The Work-up of Patients with Hypereosinophilia at a Tertiary Referral Center. Vancouver, CA.
2018. Characterization of Chronic Myelomonocytic Leukemia with TP53 mutations. Conference. Characterization of Chronic Myelomonocytic Leukemia with TP53 mutations. Vancouver, CA.
2018. CD5-Negative and CD10-Positive Mantle Cell Lymphoma: A Clinicopathologic Study of 10 Cases. Conference. CD5-Negative and CD10-Positive Mantle Cell Lymphoma: A Clinicopathologic Study of 10 Cases. Vancouver, CA.
2018. TP53 Mutations are Common in Mantle Cell Lymphoma, Including the Indolent Leukemic Non-Nodal Variant. Conference. TP53 Mutations are Common in Mantle Cell Lymphoma, Including the Indolent Leukemic Non-Nodal Variant. Vancouver, CA.
2018. Clinicopathologic and Molecular Characteristics of Myeloid Neoplasms with Non-Canonical MPL Mutations. Conference. Clinicopathologic and Molecular Characteristics of Myeloid Neoplasms with Non-Canonical MPL Mutations. Vancouver, CA.
2018. Aberrant Cytokeratin Expression in Acute Myeloid Leukemia is Associated with Complex Karyotype and TP53 Alterations. Conference. Aberrant Cytokeratin Expression in Acute Myeloid Leukemia is Associated with Complex Karyotype and TP53 Alterations. Vancouver, CA.
2018. DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML. Conference. DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML. Vancouver, CA.
2018. Design of multiplex immunofluorescence panel with immune contexture markers of nodular sclerosis classical Hodgkin lymphoma. Conference. Design of multiplex immunofluorescence panel with immune contexture markers of nodular sclerosis classical Hodgkin lymphoma. Vancouver, CA.
2016. Diffuse large B-cell lymphoma with aggressive histologic features and MYC gene rearrangement. Conference. Diffuse large B-cell lymphoma with aggressive histologic features and MYC gene rearrangement. Basel, CH.
2016. Epstein-Barr virus-positive plasmacytoma. Conference. Epstein-Barr virus-positive plasmacytoma. Basel, CH.
2014. Plasmablastic Lymphoma: A Series of 31 Patients from Single Institution. Conference. Plasmablastic Lymphoma: A Series of 31 Patients from Single Institution. Melbourne, AU.

Formal Peers

2024. Myelodysplastic Myeloproliferative Neoplasms. Palm Springs, CA, US.
2023. Updates in Classification of Myeloid Neoplasms. Invited. Virtual, US.
2023. Updates in Classification of Myeloid Neoplasms. Invited. Los Angeles, CA, US.
2023. The diagnostic needs for immune monitoring in Myeloid Malignancies. Invited. London, GB.
2023. FLT3 Mutations in Acute Myeloid Leukemia. Invited. Basking Ridge, NJ, US.
2023. Updates in Classification of Myeloid Neoplasms. Invited. Dallas, TX, US.
2022. Updates on Classification on Myelodysplastic Neoplasms and Acute Myeloid Leukemia. Invited. Bronx, NY, US.
2022. Updates in Classification of Myeloid Neoplasms. Invited. Houston, US.
2022. Morphologic correlates of cytogenetic and molecular alterations in myeloid neoplasms. Invited. Miami, US.
2022. Molecular Analysis of Measurable Residual Acute Myeloid Leukemia. Invited. Galveston, TX, US.
2022. Immunophenotypic Manifestations of Molecular Alterations in Myeloid Neoplasms. Invited. Online, US.
2021. How I Diagnose Acute Myeloid Leukemia. Invited. Tehran, IR.
2020. Molecular Diagnostic Approaches in AML/Molecular Biomarkers in Hematology. Invited. Beirut, Beirut, LB.
2020. Diagnostic Approach to Chronic Myelomonocytic Leukemia: Practical Aspects and Recent Updates. Invited. Houston, TX, US.
2020. The Role of State-of-the-Art Hematopathology in Implementing Precision Oncology for Myeloid Neoplasms. Invited. Houston, TX, US.
2020. Genotype-Phenotype Correlation in Patients with Myeloid Neoplasms: A Gateway For Effective Implementation of Personalized Medicine. Invited. Galveston, TX, US.
2019. Precision Oncology for Patients with Myeloid Malignancies: The MD Anderson Experience. Invited. New York, NY, US.
2019. Updates on Chronic Myelomonocytic Leukemia. Invited. Phnoenix, AZ, US.
2017. MDS-related Gene Muations; The Role of Molecular Testing in MDS. Invited. Dallas, TX, US.
2017. Improving MDS Outcomes from Diagnosis to Treatment: A Multidisciplinary Approach. Invited. Dallas, TX, US.
2015. B-Cell and T-Cell Clonality Testing. Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2026 - 2030
Title:	Multiomic evaluation of cellular states across tissues and RAS pathway inhibition to overcome disease progression in chronic myelomonocytic leukemia
Funding Source:	American Cancer Society
Role:	Co-I
ID:	1601323

Date:	2025 - Present
Title:	Role of targeting ATPases BRG1/BRM in therapy of AML
Funding Source:	NIH
Role:	Co-I
ID:	17661

Date:	2023 - Present
Title:	Investigating the Role of WT1 Mutations in the Pathogenesis of Acute Myeloid Leukemia (AML) with UBTF Tandem Duplication
Funding Source:	NIH
Role:	Co-PI
ID:	5UG1CA233332-05

Date:	2023 - Present
Title:	Elucidating and targeting epigenetic mechanisms and dysregulated transcriptome-based vulnerabilities to eradicate minimal residual disease Acute Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	CO-I
ID:	FRA-CA-22-045

Date:	2022 - Present
Title:	Developing novel targeted therapies of Advanced Myeloproliferative Neoplasms
Funding Source:	UTMDACC Cancer Center Support (Core) Grant - MRPA
Role:	Co-I
ID:	FP00017867

Date:	2022 - Present
Title:	Developing novel Menin Inhibitor-based combinations for therapy of AML with MLL1 rearrangement or mutant NPM1
Funding Source:	NIH CONC
Role:	CO-I
ID:	CA276036

Date:	2022 - Present
Title:	The INTERCEPT Trial (Investigating Novel Therapy to Target Early Relapse and ClonalEvolution in Acute Myeloid Leukemia)
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Co-I
ID:	RP220299

Date:	2022 - 2023
Title:	ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)
Funding Source:	NIH
Role:	Co-PI
ID:	5UG1CA233332-03

Date:	2020 - Present
Title:	A Phase III Randomized Trial of Steriods+TKI Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive ALL in Adults -CBPF EA9181A
Funding Source:	Foundation/Not For Profit
Role:	Co-I
ID:	CBPF-EA9181A

Date:	2019 - 2020
Title:	Single Cell Mapping of the Immune Microenvironment in Pediatric ALL
Funding Source:	St. Baldrick's Foundation
Role:	Collaborator
ID:	19-A0-00-1003175

Date:	2019 - Present
Title:	Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Funding Source:	PrECOG
Role:	Co-PI
ID:	0007490

Date:	2018 - Present
Title:	ECOG-ACRIN Biospecimen Bank to Support NCTN
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	00011996

Date:	2015 - Present
Title:	Lab Services Support BCRF EL112LAB
Funding Source:	Coalition of Cancer Cooperative
Role:	CO-I
ID:	EL112LAB

Selected Publications

Peer-Reviewed Articles

Turkalj, S, Radtke, FA, Stoilova, B, Mecklenbrauck, R, Groom, AJ, Jakobsen, NA, Lachowiez, CA, Metzner, M, Usukhbayar, B, Salazar, MA, Zeng, Z, Loghavi, S, Marvin-Peek, J, Körber, V, Ravandi-Kashani, F, Issa, GC, Kadia, TM, Symeonidou, V, de Groot, AP, Kantarjian, HM, Takahashi, K, Konopleva, M, DiNardo, C, Vyas, P. Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy. Blood 147(6):613-632, 2026. e-Pub 2026. PMID: 41191518.
Senapati, J, Croden, J, Garcia-Manero, G, Takahashi, K, Daver, N, Kadia, TM, Borthakur, G, Short, NJ, Jabbour, EJ, Haddad, FG, Marvin-Peek, J, Abbas, HA, Bose, P, Tang, G, Loghavi, S, Shpall, E, Ramdial, JL, Popat, UR, Champlin, RE, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. HemaSphere 10(2), 2026. e-Pub 2026. PMID: 41694734.
Chien, KS, Loghavi, S, Sasaki, K, McCue, D, Daver, N, Kadia, TM, Ravandi-Kashani, F, Short, NJ, Issa, GC, Montalban Bravo, G, Haddad, FG, Hammond, DE, Swaminathan, M, Bazinet, A, Bataller Torralba, A, Bouligny, IM, Pierce, S, Garcia-Manero, G, Kantarjian, HM, DiNardo, C. Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. Clinical Lymphoma, Myeloma and Leukemia 26(2):e223-e228.e3, 2026. e-Pub 2026. PMID: 41469316.
Azevedo, RS, Jabbour, EJ, Kantarjian, HM, Lavu, S, Loghavi, S, Jain, N, Sasaki, K, Garris, R, Takahashi, K, Ravandi-Kashani, F, Short, NJ. Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia. Blood 147(5):547-556, 2026. e-Pub 2026. PMID: 41335402.
Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Flores, L, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Wang, J, Loghavi, S, Su, X, DiNardo, C, Delwel, R, Bhalla, K. Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. HemaSphere 10(1), 2026. e-Pub 2026. PMID: 41551728.
Wei, Q, Tang, G, Li, S, Wang, S, Lin, P, Wang, W, Loghavi, S, Wang, WJ, Medeiros, LJ, Xu, J. Aberrant CD25 and Increased CD123 Expression Are Common in Acute Myeloid Leukemia with KMT2A Partial Tandem Duplication and Are Associated with FLT3 Internal Tandem Duplication. Cancers 18(2), 2026. e-Pub 2026. PMID: 41595200.
Xie, Z, Lee, DH, Hansen, DK, Loghavi, S. Demystifying the diagnosis and management of ICUS, CHIP, and CCUS. Hematology 2025(1):682-690, 2025. e-Pub 2025. PMID: 41348015.
Jen, WY, Tang, G, Kugler, E, Croden, J, Sasaki, K, Bazinet, A, Bataller Torralba, A, Montalban Bravo, G, Borthakur, G, Toruner, GA, Loghavi, S, Short, NJ, Issa, GC, Bouligny, IM, Pierce, SR, Popat, UR, Pemmaraju, N, Jabbour, EJ, Garcia-Manero, G, Bhalla, K, Ravandi-Kashani, F, Daver, N, DiNardo, C, Kantarjian, HM, Kadia, TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. British Journal of Haematology 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
Rodriguez-Sevilla, JJ, Ganan Gomez, I, Kumar, B, Thongon, N, Ma, F, Chien, KS, Kim, YJ, Yang, H, Loghavi, S, Tan, R, Ademà Llobet, V, Li, Z, Tanaka, T, Uryu, H, Kanagal Shamanna, R, Al-Atrash, G, Bejar, R, Banerjee, PP, Lynn Cha, S, Montalban Bravo, G, Dougherty, M, Fernandez Laurita, MC, Wheeler, N, Jia, B, Papapetrou, EP, Izzo, F, Duenas, DE, McAllen, S, Gu, Y, Todisco, G, Ficara, F, Della Porta, M, Jain, A, Takahashi, K, Dwyer, KC, Halene, S, Bertilaccio, MS, Garcia-Manero, G, Daher, M, Colla, S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40216768.
Short, NJ, Jabbour, EJ, Macaron, W, Jain, N, Haddad, FG, Loghavi, S, Kadia, TM, Kebriaei, P, Kugler, E, Matthews, JA, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 41120271.
Loghavi, S, Abdel-Salam, HM, Hammond, DE, Chien, KS, Patel, KP, Arun, BK, DiNardo, C. Unveiling the Origins of Pathogenic TP53 Variants in Clinical Context. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40991881.
Parisi, X, Loghavi, S. NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation. Blood 146(21):2612, 2025. e-Pub 2025. PMID: 41264323.
Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome. Leukemia 39(11):2820-2824, 2025. e-Pub 2025. PMID: 40913105.
Lachowiez CA, Asimomitis G, Bernard E, Devlin SM, Tazi Y, Creignou M, Germing U, Gattermann N, Gilkes A, Thomas I, Bullinger L, Dohner K, Malcovati L, Othman J, Dillon R, Eisfeld AK, Nicolet D, Issa GC, Daver N, Kadia TM, DiNardo CD, Ravandi F, Garcia-Manero G, Montalban-Bravo G, Russell N, Cazzola M, Dohner H, Huntly BJP, Hasserjian RP, Hellstrom-Lindberg E, Papaemmanuil E, Loghavi S. Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States. Blood Cancer Discov 6(5):425-436, 2025. e-Pub 2025. PMID: 40608896.
Bazinet A, Loghavi S, Wei Y, Bataller A, Sasaki K, Arani N, Darbaniyan F, Chien K, Hammond D, Bouligny I, Kanagal-Shamanna R, Thongon N, Tang G, Urrutia S, Kadia T, DiNardo C, Daver N, Short N, Issa G, Pemmaraju N, Jabbour E, Wang SA, Wang W, Borthakur G, Bueso-Ramos C, Ravandi F, Medeiros LJ, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
Loghavi S, Ravandi F. Beyond somatic mutations: the role of next generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia. Haematologica, 2025. e-Pub 2025. PMID: 40874334.
Fiskus W, Masarova L, Mill CP, Birdwell C, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase. Blood Adv 9(21):5598-5609, 2025. e-Pub 2025. PMID: 40829105.
Senapati J, Kantarjian HM, Kadia TM, Kekedjian J, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Short NJ, Yilmaz M, Jain N, Pemmaraju N, Abbas HA, Issa GC, Maiti A, Bravo GM, Deshmukh I, Shpall E, Kebriaei P, Popat U, Loghavi S, Thakral B, Tang G, Haddad FG, Alvarado Y, Manero GG, Ravandi F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16):e70028, 2025. e-Pub 2025. PMID: 40772501.
Arora, S, Jen, WY, Yilmaz, M, Deshmukh, I, Senapati, J, Loghavi, S, Issa, GC, Short, NJ, Kadia, TM, DiNardo, C, Borthakur, G, Jabbour, J, Pemmaraju, N, Andreeff, M, Takahashi, K, Bhalla, K, Popat, UR, Shpall, E, Oran, B, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations. Cancer 131(16), 2025. e-Pub 2025. PMID: 40782343.
Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
Wei Q, Wang SA, Garcia-Manero G, Kanagal-Shamanna R, Toruner GA, Hu S, Loghavi S, Ok CY, Medeiros LJ, Tang G. Optical Genome Mapping in Myelodysplastic Syndromes: Clinical Value and Limitations Derived from a Cohort of 236 Patients. Mod Pathol 38(10):100862, 2025. e-Pub 2025. PMID: 40780682.
Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia 39(8):2030-2034, 2025. e-Pub 2025. PMID: 40555734.
Montalban-Bravo G, Loghavi S, Li Z, Chien KS, Kanagal-Shamanna R, Bataller A, Natu A, Gurney M, Bazinet A, Hammond D, Sasaki K, Borthakur G, Swaminathan M, DiNardo CD, Kadia TM, Ravandi F, Daver NG, Short NJ, Pemmaraju N, Issa GC, Lasho TL, Finke CM, Al-Kali A, Csizmar CM, Alkhateeb HB, Gangat N, Mangaonkar AA, Bueso-Ramos CE, Tefferi A, Kantarjian HM, Garcia-Manero G, Patnaik MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv 9(19):5105-5117, 2025. e-Pub 2025. PMID: 40644618.
Wang SA, Li S, Wang W, Xu J, Thakral B, Hu S, Ok CY, Jia F, Jorgensen JL, Medeiros LJ, Ravandi F, Short NJ, Loghavi S. Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort. Arch Pathol Lab Med 150(1):72-80, 2025. e-Pub 2025. PMID: 40522873.
DiNardo CD, Fathi AT, Kishtagari A, Bhalla KN, Quintas-Cardama A, Reilly SA, Almon C, Patriquin C, Nabhan S, Healy K, Hickman D, Collins MP, Khalil A, Corrigan D, Zhao T, Piel J, Lyons K, Horrigan K, Schuck V, Martin P, Elliott G, Lahr DL, Bosinger M, D'Aco K, Smolen GA, Hentemann M, Loghavi S, Agresta S, Savona MR, Stein EM. A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies. Clin Cancer Res 31(12):2327-2338, 2025. e-Pub 2025. PMID: 40238563.
Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis. Clin Cancer Res 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 43(24):JCO2500640, 2025. e-Pub 2025. PMID: 40513054.
Azevedo RS, Fayad L, Kanagal-Shamanna R, Loghavi S, Hu S, Bueso-Ramos CE, Sasaki K, Abuasab T, Khawaja F, Goulart H, Abou Dalle I, Borthakur G, Pemmaraju N. Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 40440732.
Wang WJ, Lin P, Stewart JM, Tang G, Li S, Loghavi S, Medeiros LJ, Xu J. ALK+ Large B-Cell Lymphoma With Novel ZNF296::ALK: A Morphologic Mimic of ALK+ Anaplastic Large Cell Lymphoma. Am J Hematol 100(12):2371-2372, 2025. e-Pub 2025. PMID: 40423499.
Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
Sirenko M, Lee S, Sun Z, Chaligne R, Loghavi S, Asimomitis G, Brierley CK, Bernard E, Cai SF, Myers RM, Nadorp B, Sango J, Lallo M, Levine MF, Domenico D, Arango Ossa JE, Medina-Martinez JS, Menghrajani K, Lasry A, Mims AS, Desai H, Laganson A, Famulare C, Patel M, Lozanski G, Bolton KL, Viny AD, Roshal M, Levine RL, Papapetrou EP, Stein EM, Landau DA, Eisfeld AK, Aifantis I, Papaemmanuil E. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Cell Stem Cell 32(7):1102-1121.e5, 2025. e-Pub 2025. PMID: 40409258.
Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, Loghavi S, Nasr L, Haddad FG, Senapati J, Garris R, Takahashi K, Jabbour E. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J Hematol Oncol 18(1):55, 2025. e-Pub 2025. PMID: 40369607.
Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, Yousuf M, Natu A, Csizmar CM, Gurney M, Lasho TL, Finke CM, Kanagal-Shamanna R, Hammond D, Chien KS, Bazinet A, DiNardo CD, Kadia TM, Mangaonkar AA, Daver NG, Pardanani AD, Borthakur G, Zepeda-Mendoza CJ, Reichard KK, He R, Loghavi S, Passamonti F, Ravandi F, Sasaki K, Larson D, Garcia-Manero G, Onida F, Gangat N, Montalban-Bravo G, Patnaik MM. BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. Blood 146(7):874-886, 2025. e-Pub 2025. PMID: 40332442.
Tang G, Jain P, Hu S, Ok CY, Wang WJ, Quesada AE, Wei Q, Li S, Xu J, Loghavi S, Toruner GA, Medeiros LJ. Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1. Hum Pathol 159:105793, 2025. e-Pub 2025. PMID: 40381701.
Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
Ghosh A, Xu J, Borthakur G, Olson A, Medeiros LJ, Loghavi S. Donor-Derived SF3B1-Mutated Myelodysplastic Neoplasm/Syndrome. Ann Clin Lab Sci 55(3):434-436, 2025. e-Pub 2025. PMID: 40750227.
Chien KS, Braish JS, Li Z, Loghavi S, Bataller A, Montalban-Bravo G, Sasaki K, Kanagal-Shamanna R, Takahashi K, DiNardo CD, Swaminathan M, Kantarjian HM, Garcia-Manero G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39(5):1269-1272, 2025. e-Pub 2025. PMID: 40175627.
Toruner GA, Hu S, Loghavi S, Ok CY, Tang Z, Wei Q, Kanagal-Shamanna R, Medeiros LJ, Tang G. Clinical Utility of Optical Genome Mapping as an Additional Tool in a Standard Cytogenetic Workup in Hematological Malignancies. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361363.
Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer 131(8):e35840, 2025. e-Pub 2025. PMID: 40193193.
E S, Jelloul FZ, Nahmod KA, Short N, Leventaki V, Jia F, Xu J, Loghavi S, Wang W, Jabbour LE, Tang G, Medeiros LJ, Wang SA. Acute lymphoblastic leukaemia with T- and B-lineage defining markers. Pathology 57(6):739-745, 2025. e-Pub 2025. PMID: 40318961.
Wei Q, Jelloul FZ, Wang SA, Tang G, Li S, Lin P, Loghavi S, Wang HY, Medeiros LJ, Xu J. Concurrent Bone Marrow Acute Undifferentiated Leukemia and Mediastinal T-Lymphoblastic Lymphoma With Identical SET::NUP214 Fusion and PHF6 and EZH2 Mutations. EJHaem 6(2):e70034, 2025. e-Pub 2025. PMID: 40264515.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood 145(13):1369-1381, 2025. e-Pub 2025. PMID: 40146152.
Habib D, Jabbour E, Bataller A, Sasaki K, Tang G, Loghavi S, Li S, Senapati J, Short NJ, Jain N, Kantarjian H, Haddad FG. Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). Clin Lymphoma Myeloma Leuk 25(9):672-675, 2025. e-Pub 2025. PMID: 40222876.
Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
Wang, WJ, Loghavi, S. Acute myeloid leukemia with RUNX1::CBFA2T3 fusion. Blood 145(11):1226, 2025. e-Pub 2025. PMID: 40080002.
Gisriel SD, Aakash F, Bennett JM, Hasserjian RP, Loghavi S, DeZern AE, Santini V, Savona MR, Brunner AM, Buckstein R, Wei AH, Della Porta MG, Komrokji RS, Borate UM, Sekeres MA, Platzbecker U, Fenaux P, Roboz GJ, van de Loosdrecht A, Zeidan AM, Xu ML. Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms. Arch Pathol Lab Med 149(10):968-976, 2025. e-Pub 2025. PMID: 40059041.
Wei Q, Toruner GA, Thakral B, Patel KP, Pemmaraju N, Wang SA, Kanagal-Shamanna R, Tang G, Issa GC, Loghavi S, Medeiros LJ, DiNardo C. Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic Leukemia. Genes (Basel) 16(3), 2025. e-Pub 2025. PMID: 40149468.
Wei, Q, Hu, S, Loghavi, S, Toruner, GA, Ravandi-Kashani, F, Tang, Z, Li, S, Xu, J, Daver, N, Medeiros, LJ, Tang, G. Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia. American journal of hematology 100(3):417-426, 2025. e-Pub 2025. PMID: 39871121.
Wang P, Yang RK, Jelloul FZ, Luthra R, Routbort MJ, Chen H, Loghavi S, Ok CY, Kanagal-Shamanna R, Roy-Chowdhuri S, Medeiros LJ, Patel KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precis Oncol 9:e2400299, 2025. e-Pub 2025. PMID: 40138600.
Pemmaraju, N, Loghavi, S. Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement. Blood 145(8):898, 2025. e-Pub 2025. PMID: 39976942.
Parisi, X, Loghavi, S. Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype. Blood 145(7):784, 2025. e-Pub 2025. PMID: 39946151.
Loghavi, S, Medeiros, LJ. Contemporary approach to the diagnosis and classification of intestinal T-cell lymphomas. Human Pathology 156, 2025. e-Pub 2025. PMID: 39862928.
Gower M, Li X, Aguilar-Navarro AG, Lin B, Fernandez M, Edun G, Nader M, Rondeau V, Arruda A, Tierens A, Eames Seffernick A, Polonen P, Durocher J, Wagenblast E, Yang L, Lee HS, Mullighan CG, Teachey D, Rashkovan M, Tremblay CS, Herranz D, Itkin T, Loghavi S, Dick JE, Schwartz G, Perusini MA, Sibai H, Hitzler J, Gruber TA, Minden M, Jones CL, Dolgalev I, Jahangiri S, Tikhonova AN. An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup. Sci Transl Med 17(779):eadr2012, 2025. e-Pub 2025. PMID: 39742502.
Zeidan AM, Loghavi S. Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]. Blood Lymphat Cancer 15:39-45, 2025. e-Pub 2025. PMID: 40575712.
Sameeta F, Wang W, Jelloul FZ, Nwogbo OV, Thakral B, Xu J, Li S, Ok CY, Tang G, Jia F, Medeiros LJ, Loghavi S, Jorgensen JL, Wang SA. The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes. Arch Pathol Lab Med 149(8):717-726, 2024. e-Pub 2024. PMID: 39711284.
Nahmod KA, Miranda RN, Vega F, Thakral B, Pemmaraju N, Montalban-Bravo G, Loghavi S, Jelloul FZ, Wang W, Wang S, Muzzafar T, Patel K, Bueso-Ramos CE, Medeiros LJ, Kanagal-Shamanna R. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review. Leuk Lymphoma 66(4):1-9, 2024. e-Pub 2024. PMID: 39704386.
Wei Q, Hu S, Xu J, Loghavi S, Daver N, Toruner GA, Wang W, Medeiros LJ, Tang G. Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes. Cancers (Basel) 16(24), 2024. e-Pub 2024. PMID: 39766092.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2024. e-Pub 2024. PMID: 39665206.
Jen WY, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, Loghavi S, Daver NG, DiNardo CD, Issa GC, Abbas HA, Nasnas C, Bataller A, Urrutia S, Karrar OS, Pierce SA, Kantarjian HM, Short NJ. Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy. Blood Adv 9(4):783-792, 2024. e-Pub 2024. PMID: 39631072.
Rodriguez-Sevilla, JJ, Ademà Llobet, V, Chien, KS, Loghavi, S, Ma, F, Yang, H, Montalban-Bravo, G, Huang, X, Calvo, X, Joseph, J, Bodden, K, Garcia-Manero, G, Colla, S. The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39537648.
Wei, Q, Hu, S, Xu, J, Loghavi, S, Daver, N, Toruner, GA, Wang, W, Medeiros, LJ, Tang, G. Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms. Cancers 16(24), 2024. e-Pub 2024. PMID: 39766092.
Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2024. e-Pub 2024. PMID: 39561280.
McCall D, Abuasab T, Rodriguez-Sevilla JJ, Mohamed SF, Patnaik A, Devireddy K, Arani N, Sheikh I, Jamshidi R, Gibson A, Roth M, Nunez C, Garcia M, Chien KS, Loghavi S, Pierce SA, Sasaki K, Issa G, Cuglievan B, Kantarjian H, Garcia-Manero G. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. Leuk Res 144:107563, 2024. e-Pub 2024. PMID: 39178611.
El Hussein S, Fang H, Jelloul FZ, Wang W, Loghavi S, Miranda RN, Friedberg JW, Burack WR, Evans AG, Xu J, Medeiros LJ. T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Arch Pathol Lab Med 148(8):914-920, 2024. e-Pub 2024. PMID: 38059511.
Loghavi S, Wei Q, Ravandi F, Quesada AE, Routbort MJ, Hu S, Toruner GA, Wang SA, Wang W, Miranda RN, Li S, Xu J, DiNardo CD, Daver N, Kadia TM, Issa GC, Kantarjian HM, Medeiros LJ, Tang G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol, 2024. e-Pub 2024. PMID: 39016111.
Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract 20(12):OP2400027, 2024. e-Pub 2024. PMID: 39013130.
Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, Konopleva M, Borthakur G, Daver N, Kanagal-Shammana R, Loghavi S, Qiao W, Huang X, Schneider H, Meyer M, Kantarjian H, Garcia-Manero G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res 142:107518, 2024. e-Pub 2024. PMID: 38744144.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Rep Med 5(6):101585, 2024. e-Pub 2024. PMID: 38781960.
Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5, 2024. e-Pub 2024. PMID: 38856690.
Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma:1-10, 2024. e-Pub 2024. PMID: 38749022.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica, 2024. e-Pub 2024. PMID: 38695144.
Lilley CM, Arnold CA, Arnold MA, Booth AL, Gardner JM, Jiang XS, Loghavi S, Mirza KM. Virtual Pathology Elective, Real Education: The PathElective.com Experience as a Model for Novel Pathology Pedagogy and a Primer for Curricular Evolution. Arch Pathol Lab Med 148(5):595-602, 2024. e-Pub 2024. PMID: 37638521.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Gronbaek K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Ades L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S. Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium. Hemasphere 8(5):e64, 2024. e-Pub 2024. PMID: 38756352.
Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol, 2024. e-Pub 2024. PMID: 38603594.
Wei Q, Wang SA, Loghavi S, Fang H, Medeiros LJ, Wang W. Diagnostic utility of immunohistochemistry in detection of NPM1 mutations in acute myeloid leukemia with a patchy distribution. EJHaem 5(2):379-382, 2024. e-Pub 2024. PMID: 38633114.
Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, Montalban-Bravo G, Adema V, Wildeman B, Kanagal-Shamanna R, Bazinet A, Chifotides HT, Thongon N, Calvo X, Hernandez-Rivas JM, Diez-Campelo M, Garcia-Manero G, Colla S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun 15(1):2428, 2024. e-Pub 2024. PMID: 38499526.
Sameeta F, Fang H, Wang W, Tang Z, Wang SA, Toruner GA, Parisi X, Khoury JD, Issa G, Garcia-Manero G, Medeiros LJ, Tang G, Loghavi S. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. Am J Hematol, 2024. e-Pub 2024. PMID: 38440855.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol 204(3):898-909, 2024. e-Pub 2024. PMID: 37946611.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
Fiskus W, Piel J, Collins MP, Hentemann M, Cuglievan B, Mill CP, Birdwell C, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores L, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood, 2024. e-Pub 2024. PMID: 38437498.
Mill CP, Fiskus WC, DiNardo CD, Reville P, Davis JA, Birdwell CE, Das K, Hou H, Takahashi K, Flores L, Ruan X, Su X, Loghavi S, Khoury JD, Bhalla KN. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J 14(1):25, 2024. e-Pub 2024. PMID: 38316746.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk, 2024. e-Pub 2024. PMID: 38431521.
Nahmod KA, Sasaki K, Ok CY, Loghavi S. Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. Am J Hematol 99(2):329-330, 2024. e-Pub 2024. PMID: 37243496.
Quesada AE, Hu S, Li S, Toruner GA, Wei Q, Loghavi S, Ok CY, Jain P, Thakral B, Nwogbo OV, Kim D, Iyer SP, You MJ, Medeiros LJ, Tang G. Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma. Hum Pathol 144:71-76, 2024. e-Pub 2024. PMID: 38301962.
Dimopoulos YP, Loghavi S. Acute leukemia of ambiguous lineage with BCL11B rearrangement. Blood 143(2):183, 2024. e-Pub 2024. PMID: 38206637.
Senapati, J, Urrutia, S, Loghavi, S, Short, NJ, Issa, GC, Maiti, A, Abbas, HA, Daver, N, Pemmaraju, N, Pierce, S, Chien, KS, Sasaki, K, Kadia, TM, Hammond, DE, Borthakur, G, Patel, KP, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, DiNardo, C. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
Haddad, FG, Sasaki, K, Bidikian, A, Issa, GC, Kadia, TM, Jain, N, Alvarado, Y, Short, NJ, Pemmaraju, N, Loghavi, S, Patel, KP, Kanagal Shamanna, R, Yilmaz, M, Masarova, L, Jabbour, EJ, Kantarjian, HM. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. American journal of hematology 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
Adema V, Ganan-Gomez I, Ma F, Rodriguez-Sevilla JJ, Chien K, Yang H, Thongon N, Kanagal-Shamanna R, Loghavi S, Montalban-Bravo G, Hammond D, Gu Y, Tan R, Tan L, Lorenzi P, Al-Atrash G, Clise-Dwyer K, Bejar R, Pellegrini M, Garcia-Manero G, Colla S. IL-1beta-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes. bioRxiv, 2023. e-Pub 2023. PMID: 37808770.
Wang, SA, Jorgensen, JL, Hu, S, Jia, F, Li, S, Loghavi, S, Ok, CY, Thakral, B, Xu, J, Medeiros, LJ, Wang, W. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry Part B - Clinical Cytometry 104(5):356-366, 2023. e-Pub 2023. PMID: 37605812.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Schukow CP, Zeidan AM, Loghavi S. Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs. Arch Pathol Lab Med 147(6):631-633, 2023. e-Pub 2023. PMID: 36919991.
Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Adv 7(12):2709-2714, 2023. e-Pub 2022. PMID: 36260702.
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348, 2023. e-Pub 2023. PMID: 36977823.
El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482(6):1011-1019, 2023. e-Pub 2023. PMID: 36864257.
El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):80, 2023. e-Pub 2023. PMID: 37193700.
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. e-Pub 2023. PMID: 37183966.
Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AE. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. e-Pub 2023. PMID: 37154083.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):57, 2023. e-Pub 2023. PMID: 37088806.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J 13(1):53, 2023. e-Pub 2023. PMID: 37055414.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. e-Pub 2023. PMID: 37102976.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv. e-Pub 2023. PMID: 36884300.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
Ball S, Loghavi S, Zeidan AM. TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs. Leuk Lymphoma 64(3):1-11, 2023. e-Pub 2023. PMID: 36323304.
Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel) 12(1), 2022. e-Pub 2022. PMID: 36671709.
Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 36(12):2934-2938, 2022. e-Pub 2022. PMID: 36335264.
Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 36(12):2939-2946, 2022. e-Pub 2022. PMID: 36266326.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood 140(21):2228-2247, 2022. e-Pub 2022. PMID: 36130297.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
Yeaton A, Cayanan G, Loghavi S, Dolgalev I, Leddin EM, Loo CE, Torabifard H, Nicolet D, Wang J, Corrigan K, Paraskevopoulou V, Starczynowski DT, Wang E, Abdel-Wahab O, Viny AD, Stone RM, Byrd JC, Guryanova OA, Kohli RM, Cisneros GA, Tsirigos A, Eisfeld AK, Aifantis I, Guillamot M. The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discov 12(10):2392-2413, 2022. e-Pub 2022. PMID: 35924979.
Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. e-Pub 2022. PMID: 36163821.
Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol 35(9):1212-1219, 2022. e-Pub 2022. PMID: 35504958.
DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. e-Pub 2022. PMID: 35973199.
Cho-Vega JH, Loghavi S. Pseudo-Gaucher cells in a myeloid neoplasm with PDGFRB rearrangement: imitating the imitator. Blood 140(6):664, 2022. e-Pub 2022. PMID: 35951342.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
El Hussein S, Yabe M, Wang W, Pemmaraju N, Loghavi S, Jelloul FZ, Fang H, Medeiros LJ, Burack WR, Evans AG, Liesveld JL, Bennett JM. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. EJHaem 3(3):954-957, 2022. e-Pub 2022. PMID: 36051075.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119:106884, 2022. e-Pub 2022. PMID: 35691130.
Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia. Blood 140(1):58-72, 2022. e-Pub 2022. PMID: 35390143.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
Tashakori M, Wang W, Kadia TM, Daver NG, Montalban-Bravo G, Loghavi S, Wang SA, Medeiros LJ, Ravandi F, Khoury JD. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res 118:106860, 2022. e-Pub 2022. PMID: 35636055.
El Hussein S, Wang X, Fang H, Jelloul FZ, Wang W, Loghavi S, Vega F, Miranda RN, Muzzafar T, Manning JT, Khoury JD, Burack WR, Evans AG, Medeiros LJ. Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern D. Am J Surg Pathol. e-Pub 2022. PMID: 35575765.
Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. e-Pub 2022. PMID: 35533245.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, Bah I, Wang W, Konoplev S, Medeiros LJ, Pemmaraju N, Khoury JD, Wang SA. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343-1350, 2022. e-Pub 2022. PMID: 35279700.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Nwogbo OV, Loghavi S. Essential thrombocythemia complicating hemoglobin SC disease and presenting with priapism. Blood 139(14):2258, 2022. e-Pub 2022. PMID: 35389437.
Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97(3):E100-E102, 2022. e-Pub 2022. PMID: 34989420.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 57(3):370-376, 2022. e-Pub 2022. PMID: 34992253.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2022. PMID: 34668451.
Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev S. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol 56:151860, 2022. e-Pub 2022. PMID: 34823075.
Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
El Hussein S, Wang W, Wang SA, Fang H, Garces S, Tashakori M, Lyapichev KA, Qiu L, Wang X, Loghavi S, Medeiros LJ, Challagundla P, Jorgensen JL. Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. Leuk Res 111:106704, 2021. e-Pub 2021. PMID: 34735934.
El Hussein S, Wang W, Wang SA, Loghavi S, Wang X, Qiu L, Fang H, Medeiros LJ, Aung PP, Torres Cabala C, Jorgensen JL, Pemmaraju N, Khoury JD. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma 62(13):3296-3299, 2021. e-Pub 2021. PMID: 34304666.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-3505, 2021. e-Pub 2021. PMID: 34474640.
Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
Lyapichev KA, Loghavi S, El Hussein S, Al-Maghrabi H, Xu J, Konoplev S, Medeiros LJ, Khoury JD. Future of Education or Present Reality?. Arch Pathol Lab Med 145(11):1350-1354, 2021. e-Pub 2021. PMID: 34283888.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
Fang H, Wang W, El Hussein S, Morita K, Beird HC, Mitra A, Loghavi S, Lin P, Jabbour EJ, Khoury JD. B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL. Br J Haematol 194(6):1034-1038, 2021. e-Pub 2021. PMID: 34402058.
Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. e-Pub 2021. PMID: 34171128.
Tanaka T, Morita K, Wang F, Loghavi S, Furudate K, Sasaki Y, Little LD, Gumbs CE, Matthews J, Daver NG, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal A, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood. e-Pub 2021. PMID: 34115096.
Fang H, Yabe M, Zhang X, Kim Y, Wu X, Wei P, Chi S, Zheng L, Garcia-Manero G, Shao L, Yuan J, Shen Y, Zheng G, Tang G, Wang W, Loghavi S, Shen Q, Yuan Y, He R, Chen D, Medeiros LJ, Hu S. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol 34(6):1143-1152, 2021. e-Pub 2021. PMID: 33558656.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2021. e-Pub 2021. PMID: 33972555.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
El Hussein S, Khoury JD, Lyapichev KA, Tashakori M, Khanlari M, Miranda RN, Kanagal-Shamanna R, Wang SA, Ahmed A, Mirza KM, Crane GM, Medeiros LJ, Loghavi S. Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Mod Pathol 34(5):854-861, 2021. e-Pub 2021. PMID: 33219298.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, Li S, Pemmaraju N, Nguyen T, Medeiros LJ, Wang SA. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 106(4):1047-1055, 2021. e-Pub 2021. PMID: 32241840.
Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, Loghavi S, Gomez Mediavilla A, Tonda R, Beltran S, Gut M, Pereña Gonzalez A, d'Ámore E, Visco C, Khoury JD, Montes-Moreno S. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica 106(4):1120-1128, 2021. e-Pub 2021. PMID: 32273478.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
Silva E, Malpica A, Roma A, Ramalingam P, Kim G, Bakkar R, Loghavi S, Kim S, Shaye-Brown A, Marques-Piubelli ML, Chisholm G, Gershenson DM, Alvarado-Cabrero I. Ovarian Mucinous Neoplasms, Intestinal Type, in Premenopausal Patients, Develop in Abnormal Ovaries. Hum Pathol 108:32-41, 2021. e-Pub 2021. PMID: 33227313.
Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol 192(3):667-671, 2021. e-Pub 2021. PMID: 33238033.
Ronaghy A, Hu S, Tang Z, Wang W, Tang G, Loghavi S, Li S, Thakral B, Medeiros LJ, Muzzafar T. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol 34(2):300-313, 2021. e-Pub 2021. PMID: 33110238.
Lilley CM, Arnold CA, Arnold M, Booth AL, Gardner JM, Jiang XS, Loghavi S, Mirza KM. The Implementation and Effectiveness of PathElective.com. Acad Pathol 8:23742895211006829, 2021. e-Pub 2021. PMID: 33884295.
Kirtane T, Uberoi GS, Uberoi AS, Loghavi S, Medeiros LJ, Bhutani MS. Posttransplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract. Journal of Digestive Endoscopy 11(4):293-294, 2020. e-Pub 2020.
Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma 61(13):1-4, 2020. e-Pub 2020. PMID: 32696696.
Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33255818.
Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv 4(22):5716-5721, 2020. e-Pub 2020. PMID: 33216886.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5996, 2020. e-Pub 2020. PMID: 33214561.
Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5327, 2020. e-Pub 2020. PMID: 33087716.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi S. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw 18(10):1300-1304, 2020. e-Pub 2020. PMID: 33022638.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 191(1):e10-e13, 2020. e-Pub 2020. PMID: 32686139.
Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
El Hussein S, Patel KP, Fang H, Thakral B, Loghavi S, Kanagal-Shamanna R, Konoplev S, Jabbour EJ, Medeiros LJ, Khoury JD. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol 44(9):1235-1243, 2020. e-Pub 2020. PMID: 32590457.
Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, Wei P, Khoury JD, You MJ, Loghavi S, Tang Z, Fang H, Thakral B, Medeiros LJ, Wang W. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J 10(8):86, 2020. e-Pub 2020. PMID: 32848129.
Sukswai N, Jung HR, Amr SS, Ng SB, Sheikh SS, Lyapichev K, El Hussein S, Loghavi S, RLMC A, Miranda RN, Medeiros LJ, Khoury JD. Immunopathology of Kikuchi-Fujimoto Disease: A reappraisal using novel immunohistochemistry combinations. Histopathology 77(2):262-274, 2020. e-Pub 2020. PMID: 31854007.
Fang H, Tang G, Loghavi S, Greipp P, Wang W, Verstovsek S, Medeiros LJ, Reichard KK, Miranda RN, Wang SA. Systematic Use of Fluorescence in situ Hybridization (FISH) and Clinicopathological Features in the Screening of PDGFRB Rearrangements of Patients with Myeloid/Lymphoid Neoplasms. Histopathology 76(7):1042-1054, 2020. e-Pub 2020. PMID: 32083752.
Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791-803, 2020. e-Pub 2020. PMID: 31932844.
Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen Q, Zhou Y, Garcia-Manero G, Loghavi S, Hu AY, Wang S, Bueso-Ramos CE, Kantarjian HM, Medeiros LJ, Hu S. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. Ann Hematol 99(3):487-500, 2020. e-Pub 2020. PMID: 32006151.
Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol 33(3):367-379, 2020. e-Pub 2020. PMID: 31383966.
Thakral B, Loghavi S. Marked paraneoplastic leukemoid reaction in a patient with mesothelioma mimicking a myeloid neoplasm. Blood 135(6):457, 2020. e-Pub 2020. PMID: 32027751.
Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):328-336, 2020. e-Pub 2020. PMID: 31533521.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CY. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2020. PMID: 31804006.
Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma 60(11):1-3, 2019. e-Pub 2019. PMID: 31012358.
Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. Clin Lymphoma Myeloma Leuk 19(11):709-714, 2019. e-Pub 2019. PMID: 31446000.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol 43(10):1429-1437, 2019. e-Pub 2019. PMID: 31261288.
Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538-548, 2019. e-Pub 2019. PMID: 31115909.
Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 Mutations in Myeloid Neoplasms are Associated with Male Gender, TP53 Mutations and High-Risk Disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. e-Pub 2019. PMID: 31237017.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31109153.
Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42. e-Pub 2019. PMID: 31132650.
Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2019. PMID: 30171025.
Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2019. PMID: 29741984.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. e-Pub 2019. PMID: 30577887.
Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
Hu Z, Boddu PC, Loghavi S, Miranda RN, Goswami M, Medeiros LJ, Tam W, Orazi A, Verstovsek S, Wang SA. A Multimodality Work-up of Patients with Hypereosinophilia. Am J Hematol 93(11):1337-1346, 2018. e-Pub 2018. PMID: 30105844.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol 40(11):831-835, 2018. e-Pub 2018. PMID: 29863571.
Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. e-Pub 2018. PMID: 30054307.
Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, Khogeer H, Pierce S, Medeiros LJ, Kantarjian H, Khoury JD. Chronic Myelomonocytic Leukemia With Fibrosis is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol 42(6):799-806, 2018. e-Pub 2018. PMID: 29596070.
Loghavi S, Medeiros LJ, Javadi S, Lin P, Khoury JD, Nastoupil L, Hunt KK, Clemens MW, Miranda RN. Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthet Surg J 38(7), 2018. e-Pub 2018. PMID: 29635424.
Wang W, Routbort MJ, Loghavi S, Tang Z, Medeiros LJ, Wang SA. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res 70:97-99. e-Pub 2018. PMID: 29908419.
Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour EJ, Li S, Yin CC, Medeiros LJ, Khoury JD. Chronic Lymphoproliferative Disorder of NK-cells: A Single-Institution Review with Emphasis on Relative Utility of Multimodality Diagnostic Tools. Eur J Haematol 100(5):444-454, 2018. e-Pub 2018. PMID: 29385279.
RLMC A, Loghavi S, Zuo Z, Fayad L, Dabaja B, Medeiros LJ, Khoury JD. Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. Am J Surg Pathol 42(4):492-499, 2018. e-Pub 2018. PMID: 29309302.
Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget 9(12):10259-10271, 2018. e-Pub 2018. PMID: 29535804.
Hu Z, Hu S, Ji C, Tang Z, Thakral B, Loghavi S, Medeiros LJ, Wang W. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leuk Res 65:25-28, 2018. e-Pub 2018. PMID: 29288910.
Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 7:26, 2018. e-Pub 2018. PMID: 30323983.
Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol 44(12):1075-1079, 2017. e-Pub 2017. PMID: 28885734.
RLMC A, Medeiros LJ, Khoury JD, Salem A, Bueso-Ramos CE, Loghavi S. Characteristics and Clinical Implications of Reactive Germinal Centers in the Bone Marrow. Hum Pathol 68:7-21, 2017. e-Pub 2017. PMID: 28428103.
Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian HM, Hu S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J 7(7):e583, 2017. e-Pub 2017. PMID: 28708130.
Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD. Myeloid Neoplasms with Concurrent BCR-ABL1 and CBFB Rearrangements: A Series of 10 Cases of a Clinically Aggressive Neoplasm. Am J Hematol 92(6):520-528, 2017. e-Pub 2017. PMID: 28253536.
Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, Hu B, Oki Y, Li S. Prognostic Impact of CD5 Expression in Diffuse Large B-cell Lymphoma in Patients Treated with Rituximab-EPOCH. Eur J Haematol 98(4):415-421, 2017. e-Pub 2017. PMID: 28039906.
Salem A, Loghavi S, Khoury JD, Agbay RL, Jorgensen JL, Medeiros LJ. Herpes Simplex Infection Simulating Richter Transformation: A Series of Four Cases and Review of the Literature. Histopathology 70(5):821-831, 2017. e-Pub 2017. PMID: 27905140.
Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RN. Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol 41(4):431-445, 2017. e-Pub 2017. PMID: 28248813.
Loghavi S, Khoury JD. Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood 129(11):1563, 2017. e-Pub 2017. PMID: 28302693.
Loghavi S, Wang SA, Medeiros LJ, Jorgensen JL, Li X, Xu-Monette ZY, Miranda RN, Young KH. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma 57(12):1-9, 2016. e-Pub 2016. PMID: 27105079.
Loghavi S, Medeiros LJ. A rare histologic variant of a common lymphoma. Blood 128(25):3012, 2016. e-Pub 2016. PMID: 28007735.
Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms. Am J Clin Pathol 146(4):431-8, 2016. e-Pub 2016. PMID: 27686170.
Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma 57(8):1-5, 2016. e-Pub 2016. PMID: 26700872.
Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros LJ, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 16(7):395-403.e1, 2016. e-Pub 2016. PMID: 27268124.
Khashab T, Loghavi S, Konoplev SN, Samaniego F. Resolution of lung adenocarcinoma after discontinuation of ibrutinib. BMJ Case Rep 2016, 2016. e-Pub 2016. PMID: 27435843.
Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic Features and Outcomes of Lymphoplasmacytic Lymphoma Patients with Monoclonal IgG or IgA Paraprotein Expression. Leuk Lymphoma 57(5):1-27, 2016. e-Pub 2016. PMID: 26421453.
Aye le L, Loghavi S, Young KH, Siddiqi I, Yin CC, Routbort MJ, Liang M, Eilerman K, Medeiros LJ, Brynes RK, Bueso-Ramos C. Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. Ann Diagn Pathol 21:53-8, 2016. e-Pub 2016. PMID: 27040932.
Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. Am J Clin Pathol 145(3):418-27, 2016. e-Pub 2016. PMID: 27124925.
Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Dybkær K, Chiu A, Perry AM, Zhang S, Tzankov A, Rao H, Abramson J, Sohani AR, Xu M, Hsi ED, Zhu J, Ponzoni M, Wang S, Li L, Zhang M, Ferreri AJ, Parsons BM, Li Y, Piris MA, Medeiros LJ, Young KH. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia 30(2):361-72, 2016. e-Pub 2016. PMID: 26308769.
Agbay RL, Loghavi S, Medeiros LJ, Khoury JD. High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis. Am J Surg Pathol 40(1):e1-e16, 2016. e-Pub 2016. PMID: 26658667.
Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KP. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol 144(5):746-55, 2015. e-Pub 2015. PMID: 26486739.
Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol 90(11):1091-2, 2015. e-Pub 2015. PMID: 25808231.
Yabe M, Medeiros LJ, Wang SA, Konoplev S, Ok CY, Loghavi S, Lu G, Flores L, Khoury JD, Cason RC, Young KH, Miranda RN. Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With αβ T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol 144(4):607-19, 2015. e-Pub 2015. PMID: 26386082.
Loghavi S, Al-Ibraheemi A, Zuo Z, Garcia-Manero G, Yabe M, Wang SA, Kantarjian HM, Yin CC, Miranda RN, Luthra R, Medeiros LJ, Bueso-Ramos CE, Khoury JD. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol 171(1):91-9, 2015. e-Pub 2015. PMID: 26123119.
Loghavi S, Khoury JD, Medeiros LJ. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology 67(2):225-34, 2015. e-Pub 2015. PMID: 25556356.
Loghavi S, Khoury JD. Disseminated blastic plasmacytoid dendritic cell neoplasm. Blood 126(4):558, 2015. e-Pub 2015. PMID: 26421330.
Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8:74, 2015. e-Pub 2015. PMID: 26104577.
Loghavi S, Alayed K, Aladily TN, Zuo Z, Ng SB, Tang G, Hu S, Yin CC, Miranda RN, Medeiros LJ, Khoury JD. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 8:65, 2015. e-Pub 2015. PMID: 26055271.
Yabe M, Tang G, Garcia-Manero G, Loghavi S, Lu X, Miranda RN, Medeiros LJ, Kantarjian HM, Bueso-Ramos CE, Khoury JD. Acute Myeloid Leukemia With t (v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clin Lymphoma Myeloma Leuk 15(15):Suppl:S85-90, 2015. e-Pub 2015. PMID: 26297286.
Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3, 2015. e-Pub 2015. PMID: 25999449.
Loghavi S, Khoury JD. Unusual breast mass: lymphoma with crystal-storing histiocytosis. Blood 125(15):2445, 2015. e-Pub 2015. PMID: 26038772.
de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MT. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol 46(4):558-69, 2015. e-Pub 2015. PMID: 25666664.
Zuo Z, Maiti S, Hu S, Loghavi S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper LJ, Bueso-Ramos CE. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28(3):373-82, 2015. e-Pub 2015. PMID: 25216221.
Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol 7:74, 2014. e-Pub 2014. PMID: 25281355.
Pereira L, Petitt M, Fong A, Tsuge M, Tabata T, Fang-Hoover J, Maidji E, Zydek M, Zhou Y, Inoue N, Loghavi S, Pepkowitz S, Kauvar LM, Ogunyemi D. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis 209(10):1573-84, 2014. e-Pub 2014. PMID: 24403553.
Shah S, Loghavi S, Garcia-Manero G, Khoury JD. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol 7:26, 2014. e-Pub 2014. PMID: 24669761.
Loghavi S, Walts AE, Bose S. CINtec® PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol 41(7):582-7, 2013. e-Pub 2013. PMID: 22833355.
Orakzai RH, Nalawadi S, Cuk O, Thomson L, Elad Y, Trento A, Siegel RJ, Loghavi S. Multimodality evaluation of a rare intracardiac tumor: cardiac hemangioma. Am J Med 124(8):e3-4, 2011. e-Pub 2011. PMID: 21787898.
Loghavi S, Bose S. Polyomavirus infection and urothelial carcinoma. Diagn Cytopathol 39(7):531-5, 2011. e-Pub 2011. PMID: 20891007.
Graham KL, Zabel BA, Loghavi S, Zuniga LA, Ho PP, Sobel RA, Butcher EC. Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J Immunol 183(10):6717-23, 2009. e-Pub 2009. PMID: 19864606.
Fazli-Tabaei S, Yahyavi SH, Nouri M, Zartab H, Javid G, Loghavi S, Zarrindast MR. Dopamine receptor mechanism(s) and antinociception and tolerance induced by swim stress in formalin test. Behav Pharmacol 17(4):341-7, 2006. e-Pub 2006. PMID: 16914952.

Review Articles

Loghavi S, Medeiros LJ. Noncutaneous cytotoxic T-cell lymphomas: Recent advances and emerging concepts: A report of the 2023 Society of Hematopathology/European Association for Haematopathology T-cell lymphoma workshop. Am J Clin Pathol 164(1):36-45, 2025. e-Pub 2025. PMID: 40646676.
El Chaer F, Perissinotti AJ, Loghavi S, Zeidan AM. Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?. Leukemia 39(1):1-7, 2025. e-Pub 2025. PMID: 39496917.
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol, 2024. e-Pub 2024. PMID: 39393368.
Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway H, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Zhuoer X, Xu ML, Hasserjian RP, Loghavi S. Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS). Mod Pathol:100615, 2024. e-Pub 2024. PMID: 39322118.
Kantarjian HM, Chifotides HT, Haddad FG, Short NJ, Loghavi S, Jabbour E. Ponatinib-review of historical development, current status, and future research. Am J Hematol 99(8):1576-1585, 2024. e-Pub 2024. PMID: 38727135.
Loghavi S. SOHO State of the Art Updates and Next Questions-WHO Classification of Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):752-758, 2024. e-Pub 2024. PMID: 38866644.
Choi JK, Xiao W, Chen X, Loghavi S, Elenitoba-Johnson KS, Naresh KN, Medeiros LJ, Czader M. Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes. Mod Pathol 37(5):100466, 2024. e-Pub 2024. PMID: 38460674.
Chandra DJ, Lachowiez CA, Loghavi S. Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia. Blood Rev 64:101156, 2024. e-Pub 2024. PMID: 38040614.
Loghavi S, Kanagal-Shamanna R, Khoury JD, Medeiros LJ, Naresh KN, Nejati R, Patnaik MM. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol 37(2):100397, 2024. e-Pub 2024. PMID: 38043791.
Vachhani P, Loghavi S, Bose P. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis. Clin Lymphoma Myeloma Leuk, 2024. e-Pub 2024. PMID: 38341324.
Venugopal S, Loghavi S. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms. Pathobiology 91(1):45-54, 2024. e-Pub 2024. PMID: 37839402.
Stone, M, Lilley, CM, Tang, G, Loghavi, S, Mirza, KM. Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies. Cytopathology 34(6):530-541, 2023. e-Pub 2023. PMID: 37522274.
Stahl, M, Bewersdorf, J, Xie, Z, Porta, MD, Komrokji, RS, Xu, M, Abdel-Wahab, O, Taylor, J, Steensma, DP, Starczynowski, DT, Sekeres, MA, Sanz, G, Sallman, D, Roboz, G, Platzbecker, U, Patnaik, MM, Padron, E, Odenike, O, Nimer, SD, Nazha, A, Majeti, R, Loghavi, S, Little, R, List, A, Kim, TK, Hourigan, CS, Hasserjian, RP, Halene, S, Griffiths, EA, Gore, SD, Greenberg, PL, Figueroa, ME, Fenaux, P, Efficace, F, Dezern, A, Daver, N, Churpek, JE, Carraway, H, Buckstein, R, Brunner, AM, Boultwood, J, Borate, U, Bejar, R, Bennett, JM, Wei, A, Santini, V, Savona, MR, Zeidan, AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS). Blood Reviews 62, 2023. e-Pub 2023. PMID: 37704469.
El Hussein, S, Loghavi, S. Clinical Flow Cytometry Analysis in the Setting of Chronic Myeloid Neoplasms and Clonal Hematopoiesis. Clinics in Laboratory Medicine 43(3):411-426, 2023. e-Pub 2023. PMID: 37481320.
Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev:101072. e-Pub 2023. PMID: 36934059.
Lachowiez CA, DiNardo CD, Loghavi S. Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900407.
El Hussein S, Loghavi S. The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms. Cancers (Basel) 14(22), 2022. e-Pub 2022. PMID: 36428782.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36(7):1703-1719, 2022. e-Pub 2022. PMID: 35732831.
Ahmed A, Mirza KM, Loghavi S. Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse. Curr Hematol Malig Rep 16(5):418-421, 2021. e-Pub 2021. PMID: 34586560.
El Hussein S, Wang SA, Pemmaraju N, Khoury JD, Loghavi S. Chronic Myelomonocytic Leukemia: Hematopathology Perspective. J Immunother Precis Oncol 4(3):142-149, 2021. e-Pub 2021. PMID: 35663104.
El Hussein S, Khoury JD, Medeiros LJ, Loghavi S. Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond. Curr Hematol Malig Rep 16(3):286-303, 2021. e-Pub 2021. PMID: 33945086.
Hammond D, Loghavi S. Clonal haematopoiesis of emerging significance. Pathology 53(3):300-311, 2021. e-Pub 2021. PMID: 33685721.
El Hussein S, Lyapichev KA, Crane GM, Mirza KM, Pemmaraju N, Medeiros LJ, Khoury JD, Loghavi S. Social Media for Hematopathologists: Medical Practice Reinvented-#Hemepath. Curr Hematol Malig Rep 15(5):383-390, 2020. e-Pub 2020. PMID: 33128122.
Silva EG, Kim G, Bakkar R, Bozdag Z, Shaye-Brown A, Loghavi S, Stolnicu S, Hadareanu V, Bulgaru D, Cayax LI, Pitalua MCT, Pinto K. Histology of the normal ovary in premenopausal patients. Ann Diagn Pathol 46:151475, 2020. e-Pub 2020. PMID: 32172215.
El Achi H, Khoury JD, Loghavi S. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Curr Hematol Malig Rep 14(5):358-367, 2019. e-Pub 2019. PMID: 31346903.
Loghavi S, Wang SA. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Surg Pathol Clin 12(3):651-669, 2019. e-Pub 2019. PMID: 31352979.
Loghavi S, Khoury JD. Recent Updates on Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep 13(6):446-454, 2018. e-Pub 2018. PMID: 30311069.
Agbay RL, Jain N, Loghavi S, Medeiros LJ, Khoury JD. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 91(10):1036-43, 2016. e-Pub 2016. PMID: 27414262.
Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. J Natl Compr Canc Netw 14(6):787-92, 2016. e-Pub 2016. PMID: 27283170.
Loghavi S, Kutok JL, Jorgensen JL. B-acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol 144(3):393-410, 2015. e-Pub 2015. PMID: 26276770.
Loghavi S, Curry JL, Torres-Cabala CA, Ivan D, Patel KP, Mehrotra M, Bassett R, Prieto VG, Tetzlaff MT. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Mod Pathol 27(11):1468-78, 2014. e-Pub 2014. PMID: 24743221.

Professional Educational Materials

Loghavi S, Mirza K. Hematology Takeover. The Pathologist, 2020.

Abstracts

El Hussein S, Adlowitz D, Syposs C, Eisadawi M, Fang H, Jelloul FZ, Loghavi S, Wang W, Medeiros LJ, Evans A, Burack R, O'Malley D. STAT6 Mutational Status in Primary Medistinal B-Cll Lymphoma with STAT6 Nuclear or Cytoplasmic Expression by Immunohistochemistry. Laboratory Investigation - 2023 Annual Meeting of USCAP 103(3 / Supplement S):S1127-S1129, 2023. e-Pub 2023.
Nahmod K, Thakral B, Wang W, Aakash F, Patel K, Routbort M, Kanagal-Shamanna R, Ok CY, Tang GL, Vega F, Medeiros LJ, Wang S, Loghavi S. Bone Marrow Immunophenotype and Genotype Characteristics Assessed by Flow Cytometry and Next Generation Sequencing in 147 Patients with Myeloid Sarcoma. Laboratory Investigation - 2023 Annual Meeting of USCAP 103(3 / Supplement S):S1206-S1208, 2023. e-Pub 2023.
Kim DH, Jelloul FZ, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Patel K, Routbort M, Li SY, Vega F, Miranda R, Medeiros LJ, Ok CY. Next-Generation Sequencing Identifies Approximately One Third of Mantle Cell Lymphoma Patients with Nuclear Factor-kappa B Pathway Mutations. Laboratory Investigation - 2023 Annual Meeting of USCAP 103(3 / Supplement S):S1168-S1169, 2023. e-Pub 2023.
Tashakori M, Tapan K, Loghavi S, Tang Z, Routbort M, Ravandi-Kashani F, Khoury J. TP53-mutated Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia Have Comparable TP53 Mutational Signature and Clinical Features. Laboratory Investigation-2022 Annual USCAP 102(Supplement 1):1027-1028, 2022. e-Pub 2022.
Lilley C, Arnold M, Arnold C, Booth A, Gardner J, Jiang X, Loghavi S, Mirza K. Web-Based Pathology Education Is an Effective Curricular Adjunct: The PathElective.com Experience as a Model for Novel Pathology Pedagogy. Laboratory Investigation-2022 Annual USCAP 102(Supplement 1):381-383, 2022. e-Pub 2022.
Qiu LQ, Garcia-Manero G, Montalban-Bravo G, Yang H, Tang ZY, Patel K, Loghavi S, Ok CY, Bueso-Ramos C, Medeiros LJ, Kanagal-Shamanna R. Somatic U2AF1 Mutations Involving Codons Q157 and S34 are Associated with Distinct Clinical and Molecular Characteristics but Similar Outcomes in Patients with Myelodysplastic Syndrome. Laboratory Investigation-2022 Annual USCAP 102(Supplement 1):1004-1005, 2022. e-Pub 2022.
Evans M, Khoury J, DiNardo C, Garcia-Manero G, Yang H, Loghavi S, Montalban-Bravo G, Patel K, Quesada A, Konoplev S, Garces S, Toruner G, Bueso-Ramos C, Medeiros LJ, Kanagal-Shamanna R. Bone Marrow Pathologic Abnormalities in Myelodysplastic Syndrome (MDS) Patients with Underlying TERT/TERC Germline Alterations. Modern Pathology - USCAP 2022 35(Supplement 2):945-946, 2022. e-Pub 2022.
Venugopal S, DiNardo CD, Takahashi K, Konopleva M, Loghavi S, Borthakur G, DeZern A, Masarova L, Daver N, Short NJ, Alvarado Y, Ravandi F, Montalban-Bravo G, Sasaki K, Delumpa R, Sekeres MA, Patel B, Roboz GJ, Kantarjian HM, Garcia-Manero G. Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia(Supplement 1):S339-S339, 2021. e-Pub 2021.
Rivera D, Kantarjian H, Kadia T, Daver N, DiNardo C, Patel K, Loghavi S, Short N, Yilmaz M, Jabbour E, Garcia-Manero G, Konopleva M, Borthakur G, Ravandi F. Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia(Supplement 1):S301-S302, 2021. e-Pub 2021.
Shuai W, Chen W, Floyd K, Routbort M, San Lucas F, Kanagal-Shamanna R, Zuo Z, Loghavi S, Ok CY, Yin CC, Luthra R, Medeiros LJ, Patel K. Ultra-Rapid Reporting of TP53 Mutation in Myeloid Neoplasms by Using Next Generation Sequencing. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):891-892, 2021. e-Pub 2021.
Hussein S, Loghavi S, Medeiros LJ, Garces S, Miranda R, Wang S, Wang W. Clone Size Evolution Does Not Predict Clinical Response in Patients with Persistent PNH Clones. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):819-820, 2021. e-Pub 2021.
Tashakori M, Wang W, Wang S, Kanagal-Shamanna R, Loghavi S, Medeiros LJ, Tapan K, Daver N, Ravandi-Kashani F, Khoury J. De Novo and Therapy-Related Pure Erythroid Leukemia Harbor Distinct TP53 Genetic Alterations. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):898-900, 2021. e-Pub 2021.
Hussein S, DiNardo C, Khoury J, Fang H, Lyapichev K, Garces S, Kanagal-Shamanna R, Ok CY, Patel K, Routbort M, Medeiros LJ, Wang S, Loghavi S. Emerging WT1mut Clones Contribute to Relapse in NPM1mut AML Patients. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):818-819, 2021. e-Pub 2021.
Nezami B, Toruner G, Routbort M, San Lucas F, Yang R, Seyedjafari R, Chen H, Rashid A, Loghavi S, Roy-Chowdhuri S. Clinical Utility of NGS-Based Gene Fusion Testing in Solid Tumors. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):513-514, 2021. e-Pub 2021.
Alwash Y, Kanagal-Shamanna R, Guerra VA, Daver N, Konopleva M, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Borthakur G, Loghavi S, Takahashi K, Yilmaz M, Maiti A, Kantarjian HM, Kornblau SM, Short NJ. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. BLOOD-62nd Annual Meeting of the American-Society-of-Hematology (ASH) 136(Supplement 1):DOI: 10.1182/blood-2020-141873, 2020. e-Pub 2020.
El Elhussein S, Medeiros LJ, Lyapichev KA, Gruschkus SK, Wei P, Schlette E, Kiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li SY, Xu J, Tang ZY, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression. Blood-62nd ASH Annual Meeting & Exposition, Dec. 2020 136(Supplement 1):DOI: 10.1182/blood-2020-143122, 2020. e-Pub 2020.
Hammond K, Loghavi S, Konopleva M, Kadia TM, Daver N, Ohanian M, Issa GC, Alvarado Y, Montalban-Bravo G, Garcia-Manero G, Borthakur G, Ravandi F, Takahashi K, Kantarjian HM, DiNardo CD. Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. Blood - 62nd ASH Annual Meeting & Exposition, Dec. 2020 136(Supplement 1):DOI: 10.1182/blood-2020-141380, 2020. e-Pub 2020.
Short NJ, Kantarjian HM, Loghavi S, Huang XL, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CED, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood - 60th ASH Annual Meeting & Exposition, Dec. 2018 132(Supplement 1), 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, Kadia TM, Garcia-Manero G, Patel K, Loghavi S, Sasaki K, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce SA, Cortes JE, Ravandi F. Search ... Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib Full Text Options 5 of 42 Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood - 60th ASH Annual Meeting & Exposition, Dec. 2018 132(Supplement 1), 2018. e-Pub 2018.
Sakhdari A, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort M, Patel KP, Luthra R, Medeiros LJ, Ok, CY. RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. Blood - 60th ASH Annual Meeting & Exposition, Dec. 2018 132(Supplement 1), 2018. e-Pub 2018.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos CE, Gumbs C, Little L, Song XZ, Zhang JH, Kadia TM, Borthakur G, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM, Futreal PA, Takahashi K, Ravandi F, Short NJ. Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period. Journal of Clinical Oncology 36(15):Supplement, 2018. e-Pub 2018.
Hu BY, Patel K, Chen HC, Wang XM, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok C, Loghavi S, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Wierda WG. Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 36(15):Supplement, 2018. e-Pub 2018.
Rahman H, Khoury J, Bueso-Ramos C, McDonnell T, Salem A, Wang S, Muzzafar T, Tetzlaff M, Bell D, Khogeer H, Angelova E, Li SY, Tang GL, Hu SM, Patel K, Routbort M, Luthra R, Lin P, Medeiros LJ, Loghavi S. Aberrant Cytokeratin Expression in Acute Myeloid Leukemia is Associated with Complex Karyotype and TP53 Alterations. Laboratory Investigation-107th Annual USCAP 98(Supplement 1):546-546, 2018. e-Pub 2018.
Quesada AE, DiNardo C, Routbort M, Bueso-Ramos C, Kanagal-Shamanna R, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang S, Benton C, Kantarjian HM, Luthra R, Medeiros LJ, Patel K. DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML. Modern Pathology - USCAP 2018 31(Supplement 2):545-545, 2018. e-Pub 2018.
Hu ZH, Verstovsek S, Miranda R, Loghavi S, Tam W, Orazi A, Wang S. The Work-up of Patients with Hypereosinophilia at a Tertiary Referral Center. Laboratory Investigation-107th Annual USCAP 98(Supplement 1):522-522, 2018. e-Pub 2018.
Kanagal-Shamanna R, Luthra R, Routbort MJ, Singh R, Floyd F, Abraham R, Hai S, Yin CC, Zuo Z, Ok CY, Loghavi S, Medeiros LJ, Patel KP. Multi-Platform-Based Comprehensive Molecular Analysis of Hematological Malignancies for Somatic Mutations, Copy Number Changes and Translocations for Routine Clinical Testing. The Journal of Molecular Diagnostics 19(6):964, 2017. e-Pub 2017.
Ruiz-Cordero R, Chen W, Floyd KC, Rodriguez S, Galbincea J, Barkoh B, Routbort MJ, Luthra R, Singh R, Hatfield D, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, Medeiros LJ, Patel KP. Breaking the Turnaround Time Barrier in Next Generation SequencingBased Clinical Mutation Profiling Using an Integrated Workflow and Informatics Approach. The Journal of Molecular Diagnostics 19(6):997, 2017. e-Pub 2017.
Aung PP, Nejati R, Loghavi S, Zuo Z, Chen W, Torres- Cabala CA, Konopleva M, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD-L1 Protein and mRNA Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Modern Pathology 30(S2):337A, 2017. e-Pub 2017.
Gur HD, Loghavi S, Routbort MJ, Garcia-Manero G, Yin CC, Li S, Medeiros LJ, Khoury JD. JAK2 p.V617F Mutations Are Common in Chronic Myelomonocytic Leukemia with Fibrosis. Modern Pathology 30(S2):353A, 2017. e-Pub 2017.
Kanagal-Shamanna R, Loghavi S, Medeiros LJ, Routbort MJ, Bueso-Ramos CE, Khoury JD. Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPDMM) Associated with Germline RUNX1 Mutation Shows Characteristic Morphologic Features. Modern Pathology 30(S2):356A, 2017. e-Pub 2017.
Garces S, Medeiros LJ, Salem A, Wang SA, Bueso-Ramos CE, Khoury JD, Loghavi S. Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma with Prominent Proliferation Centers in Bone Marrow Is Associated with High Tumor Burden and TP53 Deletion. Modern Pathology 30(S2):349A, 2017. e-Pub 2017.
Salem A, Tang G, Loghavi S, Hu S, Medeiros LJ, Khoury JD. Myeloid Neoplasms with Concurrent BCR-ABL1 and CBFBMYH11 Rearrangements: Clinicopathologic Features and Treatment Implications. Modern Pathology 30(S2):374A, 2017. e-Pub 2017.
Loghavi S, Zuo Z, Gur HD, Yang H, Lu X, Bueso- Ramos CE, Medeiros LJ, Khoury JD. Differential Proteomic Signatures in Chronic Myelomonocytic Leukemia Subsets Identified by Reverse Phase Protein Array Analysis. Modern Pathology 30(S2):361A, 2017. e-Pub 2017.
Loghavi S, Routbort MJ, Kanagal-Shamanna R, Wang SA, Khoury JD, OK CY, Yin CC, Singh RR, Zuo Z, Bueso-Ramos CE, Medeiros LJ, Luthra R, Patel KP. Myeloid Neoplasms with Recurrent GNAS Mutations. The Journal of Molecular Diagnostics 18(6):960, 2016. e-Pub 2016.
Mehrotra M, Singh RR, Loghavi S, Barkoh BA, Simien C, Hernandez M, Manekia J, Behrens C, Routbort MJ, Patel KP, Kopetz S, Medeiros LJ, Wistuba II, Luthra R. Ultradeep Sequencing Using Semiconductor-Based High-Throughput Next- Generation Sequencing Platforms for Cell-Free DNA Genotyping in Patients with Solid Tumors. The Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamana R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. The Journal of Molecular Diagnostics 18(6):961, 2016. e-Pub 2016.
Quesada A, Luthra R, Patel KP, Singh R, Routbort MJ, Loghavi S, Khoury JD, Medeiros LJ, Bueso-Ramos CE, Kanagal-Shamanna R. De Novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. Modern Pathology 29(S2):371A, 2016. e-Pub 2016.
Loghavi S, Zuo Z, Doss DJ, Thompson EJ, Zhao C, Lee J, Kanagal-Shamanna R, Medeiros LJ, Bueso-Ramos CE. Bone Marrow and Extramedullary Lesions in Patients with Myeloproliferative Neoplasms Exhibit Similar miRNA Profiles. Modern Pathology 29(S2):360A, 2016. e-Pub 2016.
Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Abruzzo L, Zuo Z, Huh Y, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau SM, Borthakur G, Nguyen MH, Hu P, Medeiros LJ, Nogueras-Gonzalez GM, Huang X, Estrov Z, Bueso-Ramos CE, Cortes JE. MYC protein expression as prognostic in acute myeloid leukemia. Journal of Clinical Oncology 34, 2016. e-Pub 2016.
Salim AA, Luthra R, Ok CY, Loghavi S, Mehrotra M, Abraham R, Harmon MH, Lu X, Medeiros LJ, Patel KP, Kanagal-Shamanna R. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. The journal of Molecular Diagnostics 17(6):773, 2015. e-Pub 2015.
Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros LJ, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. The Journal of Molecular Diagnostics 17(6):766, 2015. e-Pub 2015.
Ok CY, Loghavi S, Salim AA, Chen H, Kanagal-Shamanna R, Chowdhuri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros LJ, Singh RR, Routbort MJ, Luthra R, Patel KP. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. The Journal of Molecular Diagnostics 17(6):810, 2015. e-Pub 2015.
Loghavi S, Rodriguez S, OK CY, Salim AA, Mohammad M, Abraham R, Lewing C, Villarreal JC, Patel JJ, Raines JD, Schmidt DL, Young DJ, Ojaku C, Pahn DT, Rahman IA, Reyes SR, Yap JV, Reynolds AC, Bueso-Ramos CE, Jorgensen JL, Medeiros LJ, Luthra R, Patel KP. Improving Molecular Testing in Patients with Unexpected Acute Myeloid Leukemia Using Interlaboratory and Interdisciplinary Communication. The journal of Molecular Diagnostics 17(6):768, 2015. e-Pub 2015.
Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. Clinical Lymphoma Myeloma & Leukemia 15(S2):S57, 2015. e-Pub 2015.
Loghavi S, Khoury JD, Medeiros LJ. Epstein-Barr Virus-Positive Plasmacytoma in Immunocompetent Patients. Clinical Lymphoma Myeloma & Leukemia 15(S):S216-S217, 2015. e-Pub 2015.
Loghavi S, Zuo Z, Patel K, Singh R, Zhang L, Medeiros LJ, Stingo F, Routbort MJ, Cortes JE, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Luthra R, Khoury JD. DNMT3A mutations exert a dominant adverse effect in De novo acute myeloid leukemia with concurrent FLT3 and NPM1 mutations. Clinical Lymphoma Myeloma & Leukemia 15(S):S188, 2015. e-Pub 2015.
Loghavi S, Broaddus R, Daniels M, Meric-Bernstam F, Kopetz S, Chen K, Strong L, Almohammedsalim A, Ok CY, Brusco L, Kopetz S, Lu K, Lee J, Medeiros LJ, Singh R, Patel KP, Luthra R, Routbort M. Dealing With the Incidental: Experiences Implementing the ACMG Guidelines for Reporting Germline Findings in a Comprehensive Somatic Mutation Assay. Modern Pathology 28:460A, 2015. e-Pub 2015.
Aladily T, Loghavi S, Medeiros LJ, Miranda RN. B-Cell Lymphoma, Unclassified, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma - A Series of 24 Patients. Modern Pathology 28:335A, 2015. e-Pub 2015.
Ok CY, Almohammedsalim A, Loghavi S, Luthra R, Routbort MJ, Singh R, Zuo Z, Pierce S, Garcia-Manero G, Kantarjian H, Cortes J, Ravindi F, Andreef M, Medeiros LJ, Patel KP. DNMT3A Mutation as a Molecular Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. Modern Pathology 28:370A, 2015. e-Pub 2015.
Loghavi S, Kanagal-Shamanna R, Ok CY, Almohammedsalim A, Bueso-Ramos C, Routbort MJ, Mehrotra M, Verstovsek S, Kantajaran HM, Mederios LJ, Luthra R, Patel KP. De Novo Myelodysplastic Syndromes With Fibrosis Exhibit an Increased Frequency of TP53 Mutations and p53 Overexpression. Modern Pathology 28:361A, 2015. e-Pub 2015.
Young KH, Wang SA, Medeiros LJ, Jorgenson JL, Miranda RN, Loghavi S. Flow Cytometric Immunophenotypic Characterization of Angioimmunoblastic T-Cell Lymphoma. Modern Pathology 28:390A, 2015. e-Pub 2015.
Yabe M, Medeiros LJ, Tang G, Wang SA, Konoplev SN, Bhagat G, Jabbar K, Bueso-Ramos C, Loghavi S, Hoehn D, Lu G, Li S, Young KH, Miranda RN. Evaluation of Myelodysplastic Features and Correlation With Cytogenetic Findings in Hepatosplenic T-Cell Lymphoma: Analysis of 28 Patients. Modern Pathology 28:389A, 2015. e-Pub 2015.
Jabbar K, Loghavi S, Miranda RN, Broaddus R, Fayad LE, Medeiros LJ, Young KH. CD5 Positive De Novo Diffuse Large B-Cell Lymphoma: Clinicopathologic Findings and Correlation With Outcome. Modern Pathology 28:351A, 2015. e-Pub 2015.
Aladily T, Alayed K, Loghavi S, Mederios LJ, Khoury JD. Plasmablastic Lymphoma: A Series of 31 Patients from Single Institution. Pathology, 2014. e-Pub 2014.
Ohanian M, Kantarjian HM, Rozovski U, Loghavi S, Huh Y, Abruzzo L, Garcia-Manero G, Ravandi F, Borthakur G, Stingo F, Hu P, Nguyen MH, Fox PS, Mederios LJ, Estrov Z, Bueso-Ramos CE, Cortes JE. Clinical significance of MYC expression in acute myeloid leukemia. Journal of Clinical Oncology 32, 2014. e-Pub 2014.
Ramihi EF, Hostetter WL, Pinnix CC, Loghavi S, Mederios LJ, Weston BR. Endoscopic Mucosal Resection (EMR) for the Management of Solitary Extramedullary Plasmacytoma of the Esophagus. American Journal of Gastroenterology 109, 2014. e-Pub 2014.
Loghavi S, Bueso-Ramos CE, Maiti SN, Hu S, Calin GA, Garcia-Manero G, Kantarjian HM, Mederios J, Cooper L, Zuo Z. Diagnostic and Prognostic Utility of Plasma microRNA Signatures in Patients with Myelodysplastic Syndromes. Modern Pathology 27:359A-359A, 2014. e-Pub 2014.
Loghavi S, Zuo Z, Zhang L, Stingo F, Patel KP, Singh RR, Luthra R, Routbort MJ, Mederios J, Cortes JE, Ravandi-Kashani F, Kantarjian HM, Khoury JD. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. Modern Pathology 27:359A-359A, 2014. e-Pub 2014.
Loghavi S, Xu-Monette ZY, Fayad L, Kwak LW, Dabaja BS, Mederios LJ, Yong KH. Clinical and Biological Features of Primary Testicular B-Cell Lymphoma -a Single-Institution Study of 89 Cases. Blood 124:3036, 2014. e-Pub 2014.
Loghavi S, Torres-Cabala C, Curry J, Ivan D, Bassett R, Prieto V, Tetzlaff M. Tumor Size Correlates with Survival in Melanomas Associated with Conventional or Cellular Blue Nevi or Displaying Blue Nevus-Like Features (So Called Malignant Blue Nevus). Modern Pathology 27:137A-137A, 2014. e-Pub 2014.
Estrella JS, Loghavi S, Fuller GN, Ajani JA, Rashid A. FOXP3+Tumor Infiltrating Lymphocytes in EBV-Positive Lymphoepithelioma-Like Gastric Carcinoma: Clinicopathologic Features and Survival. Modern Pathology 27:173A-173A, 2014. e-Pub 2014.
Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Huh YO, Abruzzo L, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau SM, Borthakur G, Nguyen M, Stingo F, Hu P, Fox P, Medeiros LJ, Estrov Z, E Cortes CEBAJ. MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. Blood 124:5334, 2014. e-Pub 2014.
Loghavi S, Frishberg D, Balzer B. The Prevalence of Merkel Cell Carcinoma Polyomavirus in Squamous Cell Carcinoma and Sun Damaged Skin: An Immunohistochemical Study. Journal of Cutaneous Pathology 38:129-130, 2011. e-Pub 2011.
Loghavi S, Walts AE, Chung F, Bose S. What is the Optimal Number of CINtec (R) PLUS Positive Cells for Detection of High Grade Cervical Intraepithelial Neoplasia?. Modern Pathology 24:98A-98A, 2011. e-Pub 2011.
Loghavi S, Siva EG. Low Grade Vulvar Intraepithelial Lesions: A Correlation Study among Koilocytosis, Viral Load, Ki-67, and P16. Modern Pathology 23:253A-254A, 2010. e-Pub 2010.
Loghavi S, Walts A, Bose S. CINtec (R) Dual Immunostain: A New Test for Triage of Women with Abnormal Pap Smears. Cancer Cytopathology 118(5):339-340, 2010. e-Pub 2010.
Loghavi S, Sandoval M, Balzer BL. Immunoreactivity of Smoothelin in Skin and Superficial Soft Tissue Tumors and Reactive Proliferations. Modern Pathology 23:119A-119A, 2010. e-Pub 2010.
Kwok B, Loghavi S, Hussong J, Alsabeh R. The Usefulness of Fluorescence In Situ Hybridization in Diagnosis of Myelodysplastic Syndromes. Modern Pathology 23:308A-308A, 2010. e-Pub 2010.
Loghavi S, Silva EG. Abnormal Myometrial Vasculature Explains Some Cases of Menorrhagia. Modern Pathology 22(S):225A-225A, 2009. e-Pub 2009.
Graham KL, Loghavi S, Pachynski R, Zabel BA, Butcher EC. Expression of chemokinelike receptor-1 (CMKLR1) and chemerin within the central nervous system: implications for regulation of experimental autoimmune encephalomyelitis. Multiple Sclerosis 14(S):S272-S272, 2008. e-Pub 2008.

Book Chapters

Loghavi, S, Hasserjian, RP. Cytopenias, 17-79, 2018.
Loghavi, S, Wang, S. Mixed cytoses and cytopenias, 257-279, 2018.
Loghavi S, Hasserjian RP. Cytopenias: Reactive and Neoplastic. In: Diagnosis of Blood and Bone Marrow Disorders. Springer, 2018.
Loghavi S, Wang SA. Myeloid neoplasms associated with leukocytosis and/or thrombocytosis and cytopenia(s). In: Diagnosis of Blood and Bone Marrow Disorders. Springer, 2018.
Loghavi S, Tetzlaff MT. Primary cutaneous CD4+small/medium T-cell lymphoma. In: Hematopathology of the Skin: Clinical & Pathological Approach. Wolters Kluwer Health, 2016.
Loghavi S. Quantitative PCR for Plasma Epstein-Barr Virus Loads in Cancer Diagnostics. In: Methods Mol Biol, 51-61, 2016.
Hoehn, D, Loghavi, S. Laboratory techniques used in the diagnosis of pediatric tumors, 1-5, 2015.
Hoehn D, Loghavi S. Laboratory Techniques Used in the Diagnosis of Pediatric Tumors. In: Pediatric Tumors: Pathology and Imaging. Springer, 1-5, 2015.

Books (edited and written)

Crane GM, Loghavi S. Precision Molecular Pathology of Aggressive B-cell Lymphomas. Ed(s) 1. Springer, 2024.

Letters to the Editor

Konopleva, M, DiNardo, C, Sun, Y, Jung, P, Loghavi, S, Potluri, J, Dail, M, Chyla, B, Pollyea, DA. Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. American journal of hematology 101: 577-580, 2026.
Azevedo, RS, Wang, S, Swanson, DM, Daver, N, Pemmaraju, N, Kadia, TM, Issa, GC, Yilmaz, M, Borthakur, G, Senapati, J, Jen, WY, Short, NJ, Ravandi-Kashani, F, Wang, W, Fang, H, Xu, J, Patel, KP, Tang, G, Medeiros, LJ, DiNardo, C, Loghavi, S. CD123 expression and its correlation with mutation profile in acute myeloid leukaemia. British Journal of Haematology 207: 1648-1652, 2025.
Arora S, Loghavi S, Daver N, Ravandi F, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Yilmaz M, Issa GC, McCormack J, Karrar O, Pierce S, Kantarjian H, Short NJ. Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML. Am J Hematol 100: 2155-2159, 2025.
Jen WY, Loghavi S, Bazinet A, Bataller A, Bouligny I, Daver NG, Issa GC, Arani N, Almanza Huante E, Maiti A, Montalban-Bravo G, Borthakur G, Short NJ, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian HM, DiNardo CD, Kadia TM. Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies. Am J Hematol 100: 2118-2122, 2025.
Aakash F, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes: Authors' Response to "Concerns and Issues". Mod Pathol 38: 100795, 2025.
Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant 60: 910-913, 2025.
Dimopoulos YP, Wang W, Wang SA, Loghavi S, DiNardo CD, Gerstein Y, Hu S, Tang Z, Ilagan CJL, Thakral B, El Hussein S, Xu J, Li S, Lin P, Patel KP, Ok CY, Medeiros LJ, Fang H. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol 99: 2416-2419, 2024.
Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk, 2024.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.

Less

CV information above last modified March 12, 2026

Sanam Loghavi, M.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Sanam Loghavi, M.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson